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Abbreviations and definitions 
 
AUC= Area Under the Curve 
BMI= Body Mass Index 
CVD= Cardio Vascular Diseases 
High (low) glycemic food= a food giving a high (low) postprandial increase in the 
blood glucose concentration 
IAUC= Incremental Area Under the Curve 
IQR= Inter Quartile Range 
GHSR= Growth hormone secretagogue receptor 
GI= Glycemic Index 
GL= Glycemic Load 
REE= Resting Energy Expenditure 
SD= Standard Deviation 
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The most exciting phrase to hear in science, the one that heralds new discoveries, is 
not 'Eureka!' (I found it!) but 'That's funny ...' Isaac Asimov 
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Abstract 
Background:  Several aspects of the postprandial effects of meals need further 
investigation. In particular, we were interested in focusing on whether the glycemic 
effect of meals is related to the serum concentration of hormones known to be 
involved in appetite regulation, and to hunger and food intake.                              
Objective/research questions: Will the intake of two lunch meals differing in the 
carbohydrate source, have different effects on a) the postprandial blood glucose 
concentration and b) serum levels of hormones related to appetite: insulin, ghrelin, 
leptin and growth hormone? Will possible differences in these variables be reflected 
in a) hunger during the next five hours and b) food intake at the next meal?                                                                                                                        
Methods: Eleven overweight male adults were evaluated on two separate occasions 
in a cross over fashion. The subjects consumed at noon either a meal with an 
anticipated low or high glycemic effect (meal L and H respectively). The meals were 
similar in energy and fat content, taste and energy density, but had major differences 
in carbohydrate sources (lentils or potato as main sources of carbohydrate, 
respectively). Meal H and L differed also in protein, carbohydrate and fibre content. 
During five hours after the lunch meal, hunger, plasma blood glucose and serum 
hormone levels were measured. Five hours after lunch, the ad libitum food intake was 
determined at a single meal.                                                                                                          
Results:  Glucose levels were remarkably stable after meal L and did not increase by 
more than 13 % to peak, whereas glucose levels after meal H increased by 52 % to 
peak and reached a nadir that was 8% lower than baseline values. There were 
significant differences after the two test meals in plasma ghrelin (H>L), growth 
hormone (H>L) and insulin concentration (H>L), but no differences in hunger or food 
intake were observed.                                                                                             
Conclusion: Lunch meals with appreciably differing postprandial glycemic effects do 
not affect hunger or food intake in the next meal in overweight adults in this 
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particular setting, in spite of differences in the serum level of appetite regulating 
hormones. 
          
 9 
1. General background 
The prevalence of obesity (BMI 30 kg/m2) has risen greatly world wide during the 
last 25 years. The WHO characterizes the increase in obesity as an escalating global 
epidemic, affecting both affluent and non-affluent countries. In the U.S., which is one 
of the worst affected countries in the world, a staggering 60 %(1) of the adult 
population is overweight (BMI25 kg/m2), with obesity rates approaching 20% and 
15% for adults(2) and children(3) respectively. Even more alarming is the rapidity of 
the increases in childhood obesity with prevalence having increased in a range from 2 
to more than 4 fold in the worst affected countries over the last 25 years(3). In Norway 
the problem is not as alarming. Yet, during approximately the last 30 years, there has 
been an increase in body weight of 10 kg for 40-42 year old men and 4 kg for 40-42 
year old women, a 3 fold increase in obesity rates for men in the age of 50-54 years(4) 
and a height adjusted increase of 3 kg in body weight in 9-year-olds ( L.K.Heggebø, 
personal communication, October 2003). Thus, there is a need for the problem to be 
taken seriously also in Norway.   
Overweight is associated with increased mortality and is an independent risk factor 
for diabetes and cardiovascular disease. For instance, a man with a BMI of 32 has an 
11 fold increased risk of diabetes compared with a man of normal weight, and a man 
with a BMI above 35 has a more than 40 fold risk(5). Diabetes in turn increases the 
risk for cardiovascular diseases (CVD) and other comorbidities such as nephropathy, 
retinopathy and neuropathy. Additionally, overweight increases the risk for certain 
types of cancer, sleep apnea and osteoarthritis(4).  
Traditionally, the most common way of dealing with obesity in health care has been to 
encourage the obese patient to do, in mechanistic terms, the opposite of what is 
assumed to cause excess weight, i.e.: to consume less food and spend more energy. 
With regard to diet the most common approach has been prescription of diets that 
provide an energy intake below that of energy expenditure, usually in the range of 
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3500-6500 MJ/d. Usually this is achieved using diet plans with fixed energy content, 
or by limiting the use of energy dense foods. Evaluation of the outcome of energy 
restriction interventions is difficult because few randomized trials have been done and 
various adjunctive interventions confound interpretation. However, although the 
effect of the prescription of energy restriction diets per se is difficult to evaluate, this 
evaluation might not be relevant, as no intervention study in the literature, whatever 
the method, seems to have been able to induce lasting weight loss(6) 1.  Furthermore, 
evidence for energy intake being a predictor of subsequent weight gain has not been 
found by studying the literature.  
Thus, at present the evidence for the continued use of energy restricted diets is sparse. 
Despite this, the belief that energy restriction can induce sustained weight loss, or 
should be part of a weight loss strategy still seems to influence research(7) and clinical 
practice (8). The continued prescription of energy restricted diets for weight control, 
despite lack of evidence for their effect, may partly be due to the self observed effects 
energy restriction or energy over-consumption have on body weight in the short term, 
and the belief that the increase or decrease in weight thus observed is relevant for the 
long term outcome. For the layman, but also for many clinicians, it may seem so 
logical that the obese are obese because they have overeaten, that evidence for this is 
not even sought. Yet, stating that overeating is a cause of obesity is a circular 
argument because only when an individual is fat can one say that an individual has 
overeaten; that lies in the very definition of overeating(9). Notwithstanding, there is of 
course no doubt that when energy intake exceeds energy expenditure, an increase in 
body weight occurs. This is just a trivial observation however, and tells little about 
why the obese choose to eat more than they expend. An increase in body weight of a 
few kilos by eating more than one usually does, is not particularly relevant in 
evaluating what causes obesity; rather this may just be looked upon as a confirmation 
                                            
1As there are no apparent advantages associated with weight cycling, weight loss in this paper will only refer to lasting      
weight loss if other not specified.  “Lasting” is defined as clinically relevant weight loss beyond two years since the start of 
the intervention.  
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of the fact that it is possible to change the body weight to a certain extent by 
intentionally changing the energy intake. Concerning more long term effects, and 
changes by more than a few kilos, it is paramount to remember that body weight is 
tightly regulated. For instance, the imbalance between energy expenditure and energy 
intake in lean and obese individuals during a decade is typically less than 1 % (10). 
Additionally, when deviating from the body weight an individual maintains without 
consciously restricting calories, body weight appears to be controlled by the same 
mechanisms, and to the same extent, in obese and normal weight individuals(11). 
Under controlled conditions there are indications that the resistance towards body 
weight change increases proportionally the further one deviates from the baseline 
weight(11). The resistance mechanisms operate in both directions: When body weight 
is increased by overfeeding, hunger is decreased and energy expenditure is increased. 
When body weight is decreased by underfeeding, hunger increases, and resting energy 
expenditure decreases. Unlike many other regulated biologic variables, such as blood 
pressure and electrolyte concentration in blood, body weight regulation is directly 
subject to voluntary control, i.e. one can use willpower to withstand hunger and thus 
loose weight. There are however no known reasons to us why the fact that a 
homeostasis mechanism, such as hunger, should be looked upon as a variable that 
should be rendered to the individual’s willpower to control. Continued hunger in spite 
of energy surplus is a symptom of a malfunctioning body, and the body should be 
treated as such. Thus, if body weight deviates from its desired value, one should try to 
find the cause of this derangement, -not impede the body’s attempts at reaching what 
it perceives as being the proper body weight.    
The vacancy of evidence for a successful dietary weight loss regime has prompted the 
view that weight is controlled by genetics and that attempts to lose weight will engage 
a person in a battle with his body that he at the end will loose(12). This seems too 
pessimistic given the large increase in obesity over the last few decades and the 
relative stability of the human gene pool: there has to be some factors in the 
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environment having caused this, and it is likely that modification of these factors will 
induce lasting weight loss in the obese. 
With this at hand, it is evident that changes in the lifestyle and diet during the last 
decades can provide clues to the causes of obesity. It is widely believed that diet and 
physical activity are the two single most important factors to evaluate in this respect. 
While it is well documented that physical activity generally has a weight reducing 
effect(4,13), it is highly uncertain to what extent a reduction in physical activity level 
over the last few decades can explain the increase in obesity. First of all good figures 
for the secular changes in physical activity are lacking, and secondly, to our 
knowledge, no long term intervention studies evaluating the outcome of modest 
increases in physical activity have been conducted. The evaluation of modest 
increases seems to be of most relevance as large increases may not be possible to 
achieve on a population level, and in spite of the lack of good figures, physical 
activity levels do not appear to have declined dramatically during the last decades(14). 
Interestingly, a recent prospective study(10) does not support the contention that a low 
level of physical activity may lead to obesity development.  
With regard to diet, large changes appear to have occurred in the developed countries 
not only during the last century, but also during the last 2-3 decades. First, during the 
last 2-3 decades, there has been a transition to production of foods which can meet the 
needs of a more hectic lifestyle. There has been an increase in the production of 
processed foods for fast preparation and consumption at home, but also the 
availability and consumption of fast foods and snacks outside the home, seem to have 
increased. Secondly, the diet appears to yield higher levels of postprandial 
glycemia(15). Thirdly, with the focus on fat being important for the prevention of CVD 
and obesity, there has been a large increase in the number of low fat products. 
Concordantly the intake of fat has decreased (16,17). 
In line with these changes in diet and the concomitant increase in obesity, a diet that 
gives high postprandial blood glucose values has been proposed as a cause of 
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obesity(15). Conversely, a diet that gives relatively low postprandial blood glucose 
values has been proposed as a treatment for obesity. This paper has this line of 
thought as a background hypothesis, and the present study aimed at elucidating a 
specific mechanism related to the hypothesis.  
1.1 Investigating the causes of obesity 
Trying to pinpoint the exact mechanisms behind the development of obesity is a 
difficult task as body weight is a sliding scale with obesity at one end, and under 
weight at the other. Thus defining obesity or overweight using cut-off points such as a 
BMI-value of 25 kg/m2 or 30 kg/m2 has of course no practical importance with regard 
to finding the mechanisms behind obesity; no clear cut changes occur as the BMI 
exceeds the partially arbitrary 25 kg/m2 - or 30 kg/m2 -mark, which serve as cut off 
points for overweight and obesity respectively. Therefore, the investigation of long 
term body weight regulation is all about finding out why the factors that promote 
weight gain outweigh the factors that prevent it. For instance, short-term studies that 
show that certain factors are conducive to higher energy intake in a meal or during a 
day may say very little about the effect of those factors on long term body weight 
regulation, as the body may fully compensate for the increased intake in the long 
term. The key issue is whether or not such a factor gives any input to the overall 
sensors of energy status in the body. Even though all such factors were to be 
identified it would still not suffice to say what the sum of these factors would mean 
for an individual’s body weight. Only intervention studies can reveal what will 
actually happen. Exploring mechanisms is important however, as they may guide the 
way to identifying those factors that are conducive to weight gain, although their 
relative importance is hard to quantify. If for instance a hormone can induce hunger 
by intravenous administration and a certain type of meal increases the level of this 
hormone relatively more than another type of meal, then one has a starting point for 
further investigation. If then, long term studies show that lower levels of this hormone 
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persist on a certain diet and weight loss also ensues, it would seem that one has a 
factor which could play a part in the regulation of body weight.  
1.2 The brain and adiposity signals2 
Due to the important role the brain plays in body weight regulation(18), it seems 
appropriate that a discussion of the causes of obesity includes how the brain integrates 
signals of energy sufficiency or insufficiency, and how this causes decreased or 
increased energy intake and/or energy sparing (see Figure 2). The major integration 
centre in the brain for the regulation of eating and body weight is the hypothalamus. 
Vagal afferents and various hormones act upon the arcuate nucleus of the 
hypothalamus, thus informing the brain of the energy status. Insulin, leptin, and 
ghrelin have receptors in the arcuate nucleus and all of these hormones affect adipose 
tissue mass(18,19).  (Other substances that act upon the hypothalamus are not 
commented in the present work, as only these three hormones seem to be long term 
regulators of adipose tissue mass, as will be discussed in later chapters.) Within the 
arcuate nucleus insulin and leptin both seem to exert their actions primarily through 
the melanocortin system, while ghrelin appears to exert its actions primarily by 
increasing the expression of neuropeptide Y and Agouti related protein(20). The 
integrated perception of adiposity status by the arcuate nucleus is passed on to the 
paraventricular nucleus, which in turn processes this information into autonomic 
effects and behavioural responses related to energy conservation/expenditure and 
increased/reduced energy intake.  Insulin and leptin generally reduces(21,22), while 
ghrelin increases(23) energy intake when administered intracerebroventricularly in 
                                            
2
 The brain and its relation to body weight regulation is only briefly discussed. The intricate mechanisms operating in the 
brain with regard to body weight regulation is not intended to be a central theme of the paper, but a basic overview of the 
brain’s role in body weight regulation will aid the understanding of the central hypotheses in this paper.   
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rodents.  
 
Figure 1. Interactions between hormonal fat mass signals and neural pathways that regulate food intake 
and energy expenditure, as outlined by Korner et al(20). Dashed lines indicate inhibitory effects, and the solid 
lines stimulatory effects.  Y1R denote the neuropeptide Y (NPY) receptor, MC4R melanocortin 4 receptor, 
GHsR growth hormone secretagogue receptor, AgRP agouti-related protein, POMC proopiomelanocortin, -
MSH -melanocyte–stimulating protein, LEPR leptin receptor, and INSR insulin receptor (Slightly modified 
from Korner et al(20)).  
1.3 Adiposity signals and their relation to diet 
According to Schwartz et al(18),  an adiposity mediator, i.e. a substance that informs 
the brain about fat mass status, is a substance that fulfils the following criteria: It 
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should circulate in direct or inverse proportion to the amount of adipose tissue mass 
and it should cross the blood brain barrier and interact with receptors and signal 
transduction systems in neurons in the brain known to regulate energy homeostasis. 
Exogenous administration of the compound should affect food intake and/or 
metabolic rate, and repeated infusions should alter body-fat mass if continued for 
some time. Blockade of the signal should exert the opposite effects. To this date there 
are only three known compounds that fulfil these criteria: insulin, leptin and 
ghrelin(19).  
 
INSULIN 
Insulin is the prime energy storing hormone in the body, and together with glucagon it 
plays a key role in the integration of the metabolism between adipose tissue, skeletal 
muscle and the liver. Without insulin blood sugar levels increase dramatically, 
lipolysis is increased and protein uptake by the cells is decreased. 
 Increments in the blood glucose level or amino acid level in the blood after a meal 
are the two single most important triggers of insulin secretion. With regard to 
carbohydrate type, high glycemic meals stimulate more insulin secretion than low 
glycemic meals because of relative postprandial hyperglycemia. This larger insulin 
secretion may in turn cause insulin resistance, as demonstrated by decreased whole-
body glucose disposal after insulin infusion under euglycemic conditions in 
humans(24). Interestingly, primary hyperinsulinemia produced by insulin treatment of 
normal rats lowered insulin sensitivity of muscle but not of fat(25), as measured by 
increased insulin-stimulated glucose utilization index, increased de novo lipogenesis 
and glycogen synthesis. This would promote redistribution of energy substrates to 
adipose tissue, and if other effects of insulin are upheld, lead to the same adiposity 
signalling by insulin to the brain, although qualitative changes have occurred with 
regard to its energy storing effects.  Additionally, Rodin et al(26) showed that 
hyperinsulinemia stimulates appetite, irrespective of blood sugar level, and 
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Velasquez-Mieyer et al(27) showed that reduction of hyperinsulinemia reduces the 
preference for high-carbohydrate foods. Thus, the consumption of high carbohydrate 
foods may lead to a self-perpetuating cycle of increasing hyperinsulinemia and 
increased preference for foods that are strong insulin stimulators. Based on findings 
from a recent study on severely obese adults, there are indications that these effects of 
insulin may bear relevance for long term effects of hyperinsulinemia on body weight. 
In that study, suppression of insulin secretion for 24 weeks significantly reduced body 
weight(27) (122±4.1 vs. 119.2±3.9 kg, P< 0.01).  In prospective, observational studies 
however, it is not clear whether high insulin secretion can predict subsequent weight 
gain. Whereas in four studies hyperinsulinemia actually predicted a decrease in 
weight gain(28-31), two other studies came to the opposite conclusion(32,33). Because of 
the observational nature of these studies, and the fact that insulin was measured at 
baseline only, no certain inferences on cause and effect can be drawn from these 
studies however. Individual increases or decreases in insulinemia from baseline over a 
period of time and their relation to weight change would say more about the causal 
role of hyperinsulinemia in obesity, but such measurements have to our knowledge 
not been carried out. 
LEPTIN 
Leptin is the 167-amino acid product of the ob-gene and is a hormone secreted 
primarily by white adipose tissue. The ob-gene was identified and sequenced by 
Zhang et al by positional cloning in 1994(34). Lack of leptin production causes severe 
obesity in mice(34) and humans(35), and the correlation between percentage body fat 
and serum leptin concentrations is strong both in obese and normal-weight 
subjects(36). Short term fasting however decreases leptin levels more than what would 
be expected from reduction in fat mass alone, implying that leptin is affected by 
factors not related to adipocyte size and content as well. Leptin’s 24 hour pattern 
shows a nadir after noon and a peak after midnight during normal sleep/wake and 
feeding cycles(37). When controlled for the sleep/wake and feeding cycle however, 
leptin appears to be less affected by circadian rhythm than by food intake(38). Thus the 
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observed increases in leptin during night time could be the result of the cumulative 
effect of meals during day time.  
Leptin does not seem to affect hunger acutely(39). Chronic infusion of leptin has 
produced weight loss in diet induced obese(40) mice and ob/ob mice(41). The first 
intervention study in humans using recombinant leptin induced weight loss in obese 
and lean adults(42). Later studies have been disappointing however(43,44) and leptin in 
its current form is now abandoned as an obesity treatment (C. Hukshorn, personal 
communication, September 2003).  
A possible explanation for the disappointing results is that leptin may primarily be an 
anti-undernutrition substance rather than an anti-obesity substance. Thus, as long as 
undernutrition is prevented leptin may not have further major influences on the 
amount of energy stored in the adipose tissue, because on leptins behalf  “its job is 
done” as long as energy stores are maintained at a level deemed sufficient for the 
handling of possible subsequent energy deficits in the diet(45). 
Differences in diet composition affect leptin levels. High fat diets and low glycemic 
diets stimulate less leptin during 24 hrs. relative to low fat, diets that have a higher 
glycemic effect (46,47). 
After acute feeding a change in leptin usually takes more than 4 hrs to reach statistical 
significance (38). Although leptin levels are relatively slow to change after short term 
influences such as single meals, different leptin responses have been observed 
between meals differing in macronutrient ratio. Frayn et al(48) showed that a 
carbohydrate rich meal increases leptin levels postprandially, while after a fat rich 
meal, plasma leptin decreases. To our knowledge the effects of meals differing in 
glycemic effect have not been evaluated.  
          
 19 
GHRELIN 
Ghrelin, a 28-amino acid peptide discovered in 1999(49), stimulates appetite more than 
any other known agent produced or administered peripherally(50). It was discovered 
during the search for a ligand for the growth hormone secretagogue receptor (GHSR). 
Later it has been shown that ghrelin has numerous other effects, most of which act to 
promote weight gain: it can increase food intake(50), and it can decrease metabolic 
rate(51), sympathetic nervous system activity(52) and fat catabolism(52). Ghrelin is 
synthesized primarily in the stomach and the small intestine(53) and it seems to exert 
most of its effects by acting as a link between the gastrointestinal tract, the 
hypothalamus, and the pituitary. 
 Its levels are negatively correlated with percentage body fat(54) and are increased 
upon energy restriction(55). Its levels are decreased by glucose intake(55), 
hyperglycemia(56), somatostatin(57), oxyntomodulin(58) and PYY(59). Ghrelin in turn 
blunts arginin-induced insulin increases(60) and reduces insulin levels transiently(60). 
Chronic infusion of ghrelin in rats induces severe obesity(61), and conversely, 
blockade of ghrelin signalling in the brain can cause weight loss(62). In addition, 
ghrelin seems to signal meal initiation, based on the finding that there is an increase in 
ghrelin levels shortly before meal onset, followed by a decline within an hour after the 
meal (63). Interestingly, ghrelin does not only seem to affect food intake in a transient 
manner. After intracerebroventricular injection of ghrelin in rats, food intake is 
increased in the following hour but this is not compensated for during the following 
23 hours, with cumulative food intake during 24 hours being larger after ghrelin 
injection than after saline(23). In a recent study(64) however, deletion of the ghrelin 
gene did not affect body weight in mice, indicating that ghrelin may not be a critical 
factor in long term body weight regulation. 
In humans ghrelin is suppressed by meals in lean but not obese subjects(65), indicating 
that when ghrelin levels already are relatively low, a further decrease is inhibited.  
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Unfortunately, when the relation between consumption of meals and levels of ghrelin 
has been investigated, test meals have often not been described in detail, implying that 
effects observed may have been different with different characteristics of the meals. 
Of relevance to the present paper, studies that have examined the effects of meals 
differing in glycemic effect on ghrelin levels have not been found in the literature. 
The fact that on a high fat diet ghrelin levels are lower relative to a high carbohydrate, 
low protein diet(66), may indicate that low glycemic meals may not exert a strong 
suppression on ghrelin levels.  
 
1.4 Postprandial blood glucose: regulation and 
physiological significance 
Glucose is, in addition to fat, the most important fuel for the human body. The brain, 
retina, the erythrocytes and parts of the kidney and gonads are obligate users of 
glucose as fuel, and without glucose there is a rapid decline in the function of these 
tissues. Understandably, blood glucose is a tightly controlled variable. Its regulation 
involves the central nervous system, endocrine signals acting on pancreatic cells, and 
glucose utilization by different tissues. When fasting, and after the postprandial phase 
blood glucose oscillates within a level of about 4 to 6 mmol/l. In daily life, several 
factors influence this homeostatic system, resulting in oscillations both towards lower 
and higher blood glucose levels. Hypoglycaemia, when severe enough, results in 
death in a short time, whereas fluctuations of similar magnitude in the other direction, 
as measured in mmol/l glucose, do not give any appreciable negative acute effects. 
Conceivably, there are many blood glucose raising hormones, but only one blood 
glucose lowering one. Among hormones increasing blood glucose levels are 
epinephrine, glucagon, growth hormone and cortisol, and the sole hormone that lower 
it is insulin. Whereas for instance physical activity and stress influence blood glucose 
levels, in healthy humans the largest fluctuations are most often seen postprandially, 
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caused by the consumption of meals containing carbohydrate. A major determinant of 
postprandial blood glucose levels is the rate of digestion and absorption of 
carbohydrate consumed in a meal, with postprandial glucose levels increasing with 
increasing digestion and absorption rates.  
1.4.1 Digestion and absorption of carbohydrate 
Carbohydrate is the only nutrient that elevates blood glucose directly, and therefore 
type and amount of carbohydrate are two major factors that determine postprandial 
blood glucose increments. The physiological response to meals, and thus to 
carbohydrate, starts before food is ingested, due to olfactory, visual or cognitive 
factors. This response is reflected in increasing levels of insulin, and increased 
secretion of saliva and gastric juice, to mention a few changes. On entrance in the 
mouth the enzymatic and mechanical digestion of complex carbohydrates and 
disaccharides starts. Single sugars are not enzymatically digested. Amylase from the 
salivary gland starts the breaking of the bonds between single sugar molecules in 
starch, but the enzymatic digestion is halted upon entrance in the stomach, due to the 
acid milieu encountered there. In the small intestine pancreatic amylase and brush 
border enzymes break most of the complex carbohydrates into smaller molecules; 
mainly glucose, galactose and fructose. These molecules are transported into the 
enterocytes. Thereafter the sugar molecules are released into the portal vein, and some 
of the sugar is taken up by the liver before entrance into the systemic circulation. The 
glucose that escapes uptake by the liver is largely what causes the postprandial rise in 
blood glucose concentration which can be measured in blood samples from veins or 
finger capillaries. This glucose is subsequently extracted by different tissues.   
Differences in the rate of digestion and absorption of dietary carbohydrate depend 
upon the structure of the carbohydrate, other macronutrients present in the same meal, 
pH of the meal and factors that limit the digestive enzymes’ access to the glycosidic 
bonds between the individual sugar molecules, such as non-nutritive factors 
(including antinutrients), fibre, grain capsules, how tight the sugar molecules are 
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packed together, the degree of hydration, and, possibly, yet unidentified factors. When 
comparing different starchy foods the perhaps most important factor determining 
digestion rate is the starch structure. The higher the amylose to amylopectin ratio, the 
slower is the digestion rate (67). A major reason for this is probably that amylose is less 
susceptible to enzymatic attack. The relatively lesser enzyme accessibility is believed 
to be due to the linear structure of amylose, which is associated with a higher degree 
of hydrogen bonding, and the increased number of starch-lipid complexes in amylose 
relative to amylopectin(67). 
 
                    
Figure 2. Structure of the polysaccharides amylopectin and amylose ,which both consist entirely of glucose 
molecules. The glucose molecules in both polysaccharides are joined by (14) bonds, but amylopectin also 
contains (16) bonds at the branching points. 
Slower digestion of carbohydrates not only reduces postprandial glycemia, but may 
also have effects not related to the glycemia, but to the longer transit time of these 
foods through the gastrointestinal tract. When the intestines are in contact with food, 
the secretion of several enteric hormones is altered, some of which have effects 
related to meal termination, hunger and satiety. It is therefore possible that the longer 
the transit time, the stronger will the satiety signals be, and thus the time to the next 
meal may also be longer and/or the next meal will be smaller.  However, little is 
known regarding the magnitude of the differences in levels of these hormones in 
response to carbohydrates with different transit times.   
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1.4.2 Adverse effects of hyperglycemia  
 
Chronic hyperglycemia is strongly linked to microvascular complications of diabetes 
mellitus, including neuropathy, retinopathy, and nephropathy. Additionally, 
hyperglycemia has been linked to macrovascular disease(68). Whereas evidence for 
adverse effects is less clear for postprandial elevations in blood sugar concentration, 
there is no established threshold for hyperglycemia under which adverse effects do 
not occur(69). Indeed, high postprandial blood glucose levels have been linked to 
various diseases and derangements. In a European cohort study(70) the subjects in the 
highest quintile of blood glucose level 2 hours after a glucose tolerance test had an 
odds ratio of 1.6 for mortality, and a meta regression analysis of the relationship 
between postprandial hyperglycemia and incident cardiovascular events showed that 
postprandial hyperglycemia is a risk factor also in non-diabetic individuals(71). These 
studies cannot confer evidence that elevated postprandial glucose levels are causally 
implicated in atherogenesis, in particular because a high 2 hour glucose value may 
first of all reflect a prediabetic state, which is associated with higher CVD-risk (72). 
However, Temelkova-Kurktschiev et al(73) found that postprandial glycemic spikes 
were independently and positively correlated with intima-media thickness even when 
adjusted for 2 hr glucose values in healthy individuals. This makes a causal 
relationship between high postprandial blood glucose and CVD more likely.  
The possible mechanisms for the adverse effects of hyperglycemia are discussed 
below. Primarily acute effects will be discussed here, but with occasional references 
to chronic effects where appropriate. Mechanisms of possible chronic effects on 
obesity development will be discussed in later chapters. 
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Mechanisms of direct effects 
 
The mechanisms underlying the pathologic effects of hyperglycemia are related in 
part to oxidative stress, structural changes such as glycosylation, and metabolic 
alterations. Of special relevance to postprandial hyperglycemia, adverse effects on 
endothelial function and other CVD-related outcomes occur rapidly after meals that 
induce high postprandial blood glucose levels in healthy subjects(74) and in 
diabetics(75). These effects can be prevented by the co-administration of 
antioxidants(74). Eating antioxidant-poor meals that give high postprandial glycemia 
several times a day could thus chronically challenge the integrity of the endothelium, 
and possibly increase the risk for CVD.  
Hyperglycemia has also been linked to protein glycosylation(76), basement membrane 
thickening(77), impaired cellular immunity(78), cell cycle abnormalities(79,80) and 
apoptosis in heart muscle(81). These are factors which all may contribute to CVD-
development.  
The effects that hyperglycemia have on insulin secretion and insulin action has been 
termed glucose toxicity(82). Much evidence indicates that these effects play important 
roles in the development of insulin resistance and progressive impairment in insulin 
secretion, and thus may be a causative factor in the development of diabetes. For 
instance, as little as 24 h of hyperglycemia (15.6 ± 0.3 mmol) induced a 20% decline 
in the rate of insulin mediated glucose disposal in well-controlled type I diabetics(83). 
Much lower, and more physiological increments in blood glucose levels (+ 2 mmol/l 
for 3 days) induced similar impairment in insulin action in healthy young subjects(24). 
Conversely, tight glycemic control, independent of how it is achieved, enhances 
insulin action and insulin secretion in diabetics, and may be a reason for the 
improvements in insulin production associated with the honeymoon period (the period 
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where there is a transient decreased demand for exogenous insulin) in newly 
diagnosed type I diabetics(82). 
Additionally, consumption of meals that give high postprandial glucose levels 
increases the demand for insulin. This may be important with regard to the 
development of insulin resistance as insulin infusion alone can cause insulin 
resistance (24,84,85).   
Mechanisms of indirect effects  
 
Meals that give different postprandial glucose levels may differ widely in their 
hormonal and metabolic effects. A meal of normal size that gives high initial blood 
glucose increments, may stimulate twice as much insulin as that of an isoenergetic 
meal that gives relatively low blood glucose values(86). This surge of insulin directs 
the body into an energy storing mode; insulin inhibits lipolysis and hepatic glucose 
production, and enhances lipogenesis and glycogenesis. A rapidly absorbed 
carbohydrate rich meal is for the large part absorbed within 2-4 hours, and thereafter 
the body must draw from its own energy stores to ensure that blood glucose levels are 
kept sufficiently high, unless another meal is consumed. After a meal that gives a high 
postprandial glucose level, the transition from an energy storing mode to an energy 
using one may be metabolically challenging, as the effects of the high insulin to 
glucagon ratio may persist longer than the postprandial period itself, thus limiting the 
access to stored fuels. In a study by Ludwig et al this mechanism was the likely cause 
for the increased hunger and energy intake observed after a high relative to a low 
glycemic meal. In that study there was a rapid decline in blood glucose 
concentrations, below the fasting value, and relatively large increments in the 
diabetogenic hormones glucagon, epinephrine, and growth hormone, after consuming 
the high glycemic meal(86).  
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1.4.3 Measures of the glycemic effect of foods 
The method which has been used the most to measure the glycemic effects of foods, 
is the glycemic index (GI) as it is defined by the WHO(87). The GI was originally 
introduced by Jenkins et al in 1981(88) as an alternative method for the regulation of 
the intake of carbohydrate rich foods in the diabetics’ diet. Traditionally carbohydrate 
exchange lists had been used, but Jenkins et al proposed that this method may not 
reflect the physiological effect of foods. To better estimate the effects carbohydrate 
containing foods have on postprandial glycemia, the glycemic index classification 
was developed. Glycemic index is defined as the 2 hour incremental area under the 
blood glucose response curve (IAUC) after the intake of 50 grams available 
carbohydrate from a test food relative to the IAUC after intake of 50 grams of a 
control food (either glucose or white bread) is consumed. The area below the fasting 
value is ignored (Figure 3). 
      
Figure 3.  Calculation of the glycemic index. IAUC=incremental area under the curve. Usually blood 
glucose levels are measured each 15 min during the first hour and each 30 in during the second hour, yielding 
a non-smooth line. Areas between each point of measurement are calculated using the trapezoidal rule.  
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To complement the GI-concept the Glycemic Load (GL)-concept was developed. GL 
is the product of the glycemic index (reflecting carbohydrate quality) and the quantity 
of carbohydrate ingested. This concept reflects the different impact of typical serving 
sizes of different foods on the blood glucose level. For instance: water melon has a 
high GI but a low GL, whereas ordinary rice has both a high GI and a high GL (Table 
1):  
                                  
                           Table 1. Example of foods with different GI and GL values.  
In Norway soft drinks, bread, potatoes, cakes, potato chips and rice are examples of 
high GI/GL foods regularly consumed by a large part of the population. Examples of 
different foods and their respective GI and GL are listed below (sorted by Glycemic 
Index) (Table 2).  
                  
Table 2. Various foods with their respective GI and GL values. GL values are based on typical serving sizes (in 
brackets) as defined by Foster-Powell(89), or per 100 grams of the food.  As can be seen the rank of each food 
differs if based on GL based on 100 grams of edible portion, GL based on serving sizes, or if based on GI.  
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 The GI and GL values that can be obtained from tables of GI and GL for different 
foods primarily reflect the effect a specific food has on blood sugar under the specific 
conditions when doing tests for GI. As the GI is a relative measure, the GI is assumed 
to be the same also under other conditions as long as the reference food is also tested 
under the exact same conditions as the test food. However, the primary aim of 
focusing on a food’s GI is to evaluate what effect that food has on the blood glucose, 
in absolute terms. When considering this, a range of factors may influence the impact 
different foods has on blood glucose level. These will be considered below. 
Factors affecting postprandial glucose response    
 
Nutrition status and diet 
Fasting increases the blood glucose increments after the consumption of a meal 
containing carbohydrate, as compared to the well fed state. One study showed that 
after a prolonged fast glucose tolerance is greatly reduced as compared to an 
overnight fast(90). Moreover, as compared to an overnight fast, glucose tolerance is 
improved if a meal containing carbohydrate has been consumed in the hours before a 
carbohydrate load. This is referred to as the Staub-Traugott effect(91,92) or the second 
meal effect(93). Also, the quality of the first meal is a major determinant of second 
meal glucose response. For instance, when a low glycemic, high carbohydrate meal is 
consumed for hours before the second meal, glucose tolerance is improved relative to 
a high glycemic meal (with equal carbohydrate amount)(93). The mechanism behind 
this effect appears to be linked both to the type and amount of carbohydrate, as 
indicated by the absence of any improved glucose tolerance after the consumption of 
a low glycemic, low carbohydrate meal compared to a, high glycemic, high 
carbohydrate one(94). This suggests that the glucose tolerance in the hours after 
different meals is primarily affected by insulin/carbohydrate dynamics in the 
postprandial state, and not to overall energy status or other factors. In other words, 
four hours after a low glycemic, high carbohydrate meal the body is closer to being in 
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an energy storing mode than after a high glycemic one, because after the high 
glycemic one, nutrient absorption is faster. Thus, the switch from utilizing nutrients 
from the intestine directly for energy production to drawing upon its own energy 
stores, comes earlier after a high glycemic meal. The consumption of a second meal 
four hours after a low glycemic one may thus be seen as a continuation of the first 
meal, whereas the consumption of a high glycemic meal as the first one, truly makes 
the next meal a separate event. While this first-meal-extension-effect may be part of 
the mechanism, there appears to be other factors which are involved as well, because 
glucose tolerance is improved even when a low glycemic meal is eaten as long a time 
as the evening before a standardized breakfast(95). More studies are needed to clarify 
for how long the effects of a meal on subsequent glucose tolerance persist, and what 
factors in the meal that predict the subsequent glucose tolerance.  
Considering more long term effects, after a period on a low carbohydrate diet, glucose 
tolerance may be reduced(96). In other words, when the body is primed for the 
handling of glucose from the diet, be it due to inter-meal effects, or longer term 
adaptations, this appears to result in an improved glucose tolerance.  
Exercise  
Short bouts of physical exercise which do not lower glycogen, do not improve post 
exercise glucose tolerance acutely(97,98), although after a prolonged exercise bout, with 
a marked reduction in glycogen stores, the glucose tolerance is increased(99). Exercise 
in the postprandial period however has a profound impact on the glucose response. 
Even light postprandial exercise can blunt glucose increments even after a high 
glycemic meal(100). 
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Age and gender 
When adjusted for fat mass and lean body mass, age(101) does not appear to have a 
major effect on glucose tolerance. We have not been able to find literature which 
evaluates the impact of gender on glucose tolerance.  
Time of day 
Glucose tolerance appears to be reduced during the afternoon and evening(102) . 
Medications 
Various medications, such as corticosteroids and unselective -blockers, can decrease 
glucose tolerance. 
Accuracy of the glycemic index and the glycemic load, and 
practical application 
 
Although the importance of avoiding high postprandial blood glucose levels is widely 
appreciated, the use of the glycemic index and glycemic load concept as a means of 
achieving this has been questioned. The critique has been centred on two main issues: 
the accuracy of the GI and GL values, and the practical application of the concepts. I 
will discuss these two issues further. 
Accuracy of the glycemic index and the glycemic load 
 
The concept of the GI is precisely defined(103). The GI’s for several seemingly similar 
foods can differ widely however. For instance, high amylose rice may have a GI as 
low as 37(67) and jasmine rice may have a value as high as 109(104). Botanical variety 
does not by far explain the whole variability in the GI values however. In a recent 
interlaboratory study(105) the botanical variety issue was eliminated by testing the same 
foods in different laboratories. The mean GI values differed by up to 33.5 units for the 
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same food, a difference which must be considered to be rather large. The standard 
deviation for each food tested in the different laboratories was also large. Rice, with 
an average GI of 71, had a standard deviation which was in a range from 8.1 to 75.9 
in the different laboratories respectively, implying that there is a need for better 
methods to reduce within-subject variation. A study that specifically evaluated the 
within-subject variation found that a total of four repeated tests were required to rank 
three different foods with GI’s of 61, 79 and 100 correctly, in all of 12 subjects(106). 
There is room for debate whether the glycemic index can be used to reflect the true 
effects of each food on glycosylation, insulin secretion, and other markers related to 
the glycemic effect of foods. While it is well documented that the GI to the very least 
provides a crude measure of glycemic effects of different foods, it says nothing 
directly about the shape of the blood glucose curve. For instance, it is not known 
whether a food which gives blood glucose values that reach higher peaks than other 
foods gives more adverse health effects than foods that yield a higher GI, but do not 
reach as high a peak, if such differences exist at all. Additionally, different diseases 
and conditions could differ with regard to whether the peak blood glucose or the GI is 
the prime indicator of adverse effects. This also complicates the use of the GL, as this 
concept tells even less about the shape of the curve. Ludwig(107) however, argues that 
GL’s applicability is fairly good based on the following findings: (1)calculated GL 
can predict the glycemic response (i.e. 2 hr IAUC) to individual foods across a wide 
range of serving sizes and (2)in several epidemiological studies, GL is independently 
associated with important health outcomes. These findings do not assure however, 
that individuals choosing a low-GL diet consisting of a small amount of low-GI foods 
will have the same health outcomes as those choosing a low-GL diet consisting of a 
large amount of low-GI foods. For instance, a serving of two different foods with the 
same GL but different GI, gives the same IAUC, but other effects such as transit time 
through the gastrointestinal tract and the effects of continuous, long lasting absorption 
vs. rapid absorption of carbohydrate is not reflected by GL directly.  
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Foods are more often eaten in a mixed meal than on their own. Initially there were 
concerns that this would render the concept of the GI of limited utility in a normal 
diet(108,109). Later studies have however shown that the glycemic response to mixed 
meals can be predicted with a rather good accuracy using standard methods(110,111). 
This implies that other macronutrients do not affect the glycemic response 
appreciably in normal mixed meals.  
The estimation of the GL of foods, based on the respective GI’s, includes another 
factor which is subject to variation (the amount of carbohydrate in each food). Thus, 
the GL is a more inaccurate measure than the GI.   
Practical application 
 
The GI/GL is a tool which is developed to aid in food choice, and does not directly 
harbour information on any other aspects of the diet. Thus, the effects of the use of 
GI/GL are highly dependent on the way it is used. The skilled nutrition educator 
should be able to convert knowledge about the GI/GL into practical and feasible 
advice that will reduce a patient’s glycemia without even mentioning the concept, 
while at the same time assuring that other aspects of the diet are not compromised. 
This can be done by focusing on which food types and what amounts of individual 
foods to be chosen, rather than focusing on each food’s GL/GI, e.g. “eat more 
legumes and less white bread”. As for the layman, a one-sided focus on the GI/GL’s 
of foods may lead to unwanted changes in the diet, as with any other narrow 
approach, be it low-fat, high-fibre, or low calorie diets. This means that care should 
be taken that information on the GI/GL of a food comes hand in hand with a 
minimum of information on how to use it.  
The fact that different botanical varieties of similar foods may have different GI-
values is considered by some to be problematic(112). An alternative view is that this 
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gives the consumer the possibility to choose better foods without making large 
changes in the diet.  
Due to the uncertainties concerning the accuracy of the GI/GL, in the present work, 
the term glycemic effect or postprandial glycemic effect is used when relating to 
blood glucose levels after food intake.  
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1.4.4 High glycemic diet and obesity 
 
The average glycemic effect in the diet appears to have risen in the US in recent 
years(113) and it is likely that this has happened in Norway as well, based on the fact 
that carbohydrate consumption has increased concomitantly with increases  in 
consumption of sugar(16) and changes in food-processing technology. This raises the 
question whether the increase in the glycemic effect in the Norwegian population 
could be one of the factors that can explain the obesity epidemic. Several studies have 
addressed the issue, some of which will be reviewed here. 
Short term studies in humans (single day studies) 
 
Reviews that have evaluated the effects of low- vs. high glycemic meals in single day 
studies on satiety, hunger and food intake have come to different conclusions. A 
review by Raben concluded that there is no convincing evidence that low glycemic 
meals are beneficial in this respect(114), whereas other reviews are more positive(15,115). 
Pawlak et al(116) criticized Raben’s meta-analysis of short term studies on 
methodological issues and argued that several of the studies included in the analysis 
were either underpowered or irrelevant to the hypothesis under question. In particular, 
Pawlak et al noted that 19 of these studies did not demonstrate differences in 
glycemic responses, or energy content was not controlled. Therefore Pawlak et al 
argued that these studies should not have been included in the analysis. Based on 
these considerations Pawlak (116)  et al re-evaluated Raben’s meta-analysis and found 
that among 12 remaining studies, six reported a statistically significant result in 
favour of the low glycemic meal, 3 showed a trend in favour of the low glycemic 
meal, one reported no difference between meals, one reported a trend in favour of the 
high glycemic meal and none reported a significant result in favour of the high 
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glycemic meal. Pawlak et al therefore concluded that meals with a lower impact on 
postprandial blood glucose levels may play a significant role in increasing satiety, 
reducing hunger or reducing food intake. 
As illustrated by the different views as discussed above, the results from short term 
studies may not be clear cut, but it is evident that consumption of low glycemic foods 
relative to high glycemic foods has effects which to the very least are related to satiety 
and food intake under certain circumstances, and thus may play a role in long term 
body weight regulation. When evaluating the strength of the evidence from short term 
studies for effects of a low glycemic diet on body weight regulation, it is paramount 
to remember what a small surplus of energy intake which is needed at meals to gain 
several kilos of body weight over a longer period. Thus even half a bread slice with 
butter and spread (0,385 MJ) extra at a meal once a day for a year would amount to 
3,8 kg extra body weight (under the hypothetical condition that all other factors are 
kept the same). Such small differences are not likely to be detected in single meal 
studies. All the more, this puts the study(86) that showed that the energy intake after a 
single high glycemic meal vs. a low glycemic meal was  2.6 MJ larger (or the 
equivalent of 3.5 bread slices with butter and spread), in a different light, and 
downplays the importance of studies which have not detected measurable differences. 
However, in most of the studies in this area the test meals have been given for 
breakfast. Little is known concerning the effects of a single meal eaten at lunch, on 
subsequent food intake. Usually lunch is eaten as the second meal of the day. This 
difference may influence subsequent food intake due to the second meal effect. Most 
likely this will lead to smaller differences in food intake, probably due to better 
regulation of blood glucose and, thus, better access to metabolic fuels, as outlined 
above.  
Additionally, few of the studies have examined the effects of mixed, normal meals; 
the test foods have often been one separate food eaten alone, or they have not 
represented meals free living subjects are likely to choose.  
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Finally, few of the studies have included obese subjects. The inclusion of obese 
subjects is important because the obese might have responses to high glycemic meals 
which are different from the lean subjects’ responses. Different responses to foods in 
lean and obese could thus shed light on which factors that may be conducive to 
weight gain. Conversely, lack of observed differences in acute energy intake in a 
heterogeneous or lean population, do not mean that high glycemic meals are not a 
cause of increased acute energy intake in the obese. If future studies show that 
consumption of high glycemic meals indeed plays a major role in the development of 
obesity, the probable differences between the lean and the obese in the response to 
high glycemic meals may provide part of the answer to why some get obese and 
others do not.  As previously mentioned results from medium or longer term 
intervention studies bear much stronger relevance to what the long term outcome of a 
low glycemic diet may be. To date no long term3 study has been conducted. The 
results from several medium term studies are at hand however.   
                                            
3
 Long term in this paper is considered as more than 2 years. 
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Medium term studies (5 weeks to 12 months) 
 
Given the poor long term outcome of energy restricted diets, interventions that induce 
weight loss when a diet is eaten ad libitum tell more about potential outcome in the 
long term. To our knowledge, only two studies have evaluated the effects of an ad 
libitum low glycemic diet vs. other ad libitum interventions. The first one compared 
the effects of a low- vs. a high glycemic diet during pregnancy(117). The maternal 
weight gain was much less in the low glycemic group (11.8 kg vs. 19.7 kg; P<0.01) 
and the infants born to women in the low glycemic group had lower adiposity (301 
grams vs. 402 grams; P<0.01).  The second study tested a 5 week low glycemic diet 
vs. a 5 week high glycemic diet in moderately obese men (118). While there were no 
differences in body weight, the low glycemic diet was associated with a decrease in 
fat mass by about 700 grams (P<0.05), and a tendency of increased lean body mass (P 
<0.07).  
A low glycemic ad libitum diet has also been compared to other energy restricted 
regimens. The first one was a retrospective, nonrandomized cohort study of children 
attending an outpatient pediatric obesity program, comparing the effects of a low 
glycemic diet with those of a conventional reduced-fat diet for about 4 months(119). 
Body mass index (-1.53 kg/m2 vs 0.06 kg/m2, P<0.001) and body weight (-2.03 kg vs 
+1.31 kg, P<0.001) decreased more in the low glycemic group compared with the 
reduced-fat group. Because this study was retrospective and non-randomized, these 
results must be viewed as preliminary however. The second and longest study of this 
type was a 12 months randomized controlled trial(120) consisting of a 6 month 
intervention and a 6 month follow up. Sixteen obese adolescents were included in the 
study and were either counselled to follow a conventional reduced fat, mildly energy 
restricted diet, or an ad libitum low glycemic diet. Although both groups changed the 
composition of the diet according to what they were prescribed, after 12 months fat 
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mass had decreased by 3 kg in the low glycemic group and had increased by 1.8 kg in 
the conventional diet group. This result may indicate that a low glycemic diet causes 
less hunger and that it is easier to follow. Additionally this implies that a low 
glycemic diet may facilitate reduced energy intake without subjects making a 
conscious effort at eating less and, conversely, on a high glycemic diet, energy 
restriction is made difficult.   
The weight reduction per se achieved in the few above mentioned studies do not 
warrant the use of low glycemic diets for obesity treatment. However, there are other 
findings from these and other studies which seem to make a low glycemic diet rather 
promising in obesity treatment. On energy restricted diets a low glycemic diet relative 
to a high glycemic one causes less spontaneous energy intake after energy restriction 
has been discontinued(121), REE is better preserved(121) and nitrogen balance is less 
negative(121). All these factors indicate that weight loss can be maintained more easily 
on a low glycemic diet as compared to a high glycemic one. Additionally, in the few 
studies at hand, there are no indications that the effects on body weight are transient 
by following a low glycemic diet. After the 6 month intervention in the study by 
Ebbeling et al, body weight did not increase during the 6 month follow up(120).  
Diets that are less palatable than the diet one is used to, are likely to be abandoned in 
the long term and may explain why subjects eat less than they usually do and 
therefore loose weight. While this could be a possibility with low glycemic diets, 
there are no clear indications that the high glycemic diets these were compared to, 
were evaluated as more or less palatable than the other. Thus, in medium term studies 
the differences in body weight from baseline in absolute figures may not reflect the 
true weight loss on a low glycemic diet. However, the differences between the high- 
and the low glycemic regimen in the above mentioned studies should be considered as 
real, as all regimens limit snack foods and represent a prudent diet.  
Whereas it is not the equivalent of a low glycemic diet, -glucosidase inhibitors such 
as acarbose, provide an interesting parallel to the effects of postprandial glycemia on 
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body weight. -glucosidase inhibitors reduce postprandial glycemia(122) by delaying, 
and partly inhibiting, the absorption of carbohydrate, and generally these agents have 
a weight stabilizing or mild weight reducing effect in patients with diabetes or 
impaired glucose tolerance(122). Few studies however have specifically investigated 
the effects of -glucosidase inhibitors on body fat mass, implying that the modest 
weight losses observed could be confounded by changes in body composition. 
Furthermore the effects may be different in subjects without reduced glucose 
tolerance or diabetes. 
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1.5 A hypothetical model for development of obesity on a 
high glycemic diet 
Based on the above mentioned considerations, a high glycemic diet could be one of 
the contributing factors in the etiology of obesity. A proposed mechanism for how 
high glycemic meals could lead to obesity is outlined below (Fig. 4).            
 
                Figure 4. A hypothetical model for the development of obesity on a high glycemic diet.  
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High postprandial glucose stimulates high insulin secretion and may induce 
glucotoxicity, which, together with a high insulin secretion, may lead to insulin 
resistance which again increases insulin secretion. Insulin secretion can also be 
further increased due to acute postprandial effects of high glycemic meals: appetite 
control is diminished, leading in turn to bigger meals and a higher preference for high 
glycemic foods. These factors lead to cycles of continually exacerbating 
hypersecretion of insulin. In susceptible individuals, this hyperinsulinemia may shift 
the adipostat in the brain to higher adiposity levels, because of reduced central 
relative to peripheral effects of insulin. Additionally, fewer meals may lead to reduced 
muscle mass(123), which in turn may aggravate insulin resistance(124). In total, the shift 
in perceived adiposity level by the brain leads to increased hunger, and long term 
energy intake which is larger than the amount expended. Thus obesity ensues. 
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2. Objectives 
As discussed above several aspects of the responses to high vs. low postprandial 
blood glucose need further investigation. One primary aim of this study was to 
evaluate the effect of two normal lunch meals, with a major difference in their 
glycemic effect, on serum levels of hormones related to appetite. Leptin, ghrelin and 
insulin were measured as these three hormones may be important with regard to long 
term outcome on body weight of different diets, as outlined above. Furthermore we 
wanted to investigate whether potential differences in these hormones would lead to 
differences in hunger and food intake. In addition, growth hormone was measured due 
to its counter regulatory effects on hypoglycaemia, which may be observed after the 
ingestion of high glycemic meals. More specifically, the research questions of the 
present study were:  
1) Will equienergetic intakes of two lunch meals with equal fat content and 
energy density, but with a major difference in the carbohydrate source and also 
differences in other nutrients, have different effects on a) the postprandial 
blood glucose concentration and b) serum levels of hormones related to 
appetite: insulin, ghrelin, leptin and growth hormone? 
2) Will possible differences under 1) in glycemic effect and hormones be 
reflected in hunger, as estimated by visual analogic scale (VAS), and food 
intake, as estimated by the amount eaten in the next meal five hours later? 
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3. Methods 
Subjects 
First, we tried to recruit subjects by contacting governmental work sites and by 
putting up posters at the University of Oslo, but this was to no avail. 11 healthy men 
between the age of 40 and 71 were then recruited through an advertisement in the 
local newspaper “Aftenposten Aften”. All subjects underwent screening at the 
Institute of General Practice and Community Medicine at the University of Oslo. At 
the screening the subjects were informed about possible adverse outcomes of taking 
part in the study, their right to withdraw from the study without giving a reason, their 
anonymousness and that the study was as approved by the regional ethics committee. 
They were also informed in general terms about the purpose of the study. After filling 
out a form where they accepted the terms of the study, they underwent a glucose 
tolerance test by drinking 50 grams of glucose in 1.5 dl water. All subjects but one 
had normal glucose tolerance (one subject had a level of 8.1 mmol/l 2 hrs. after 
drinking the glucose solution), all subjects were overweight (mean BMI: 32,4 [range: 
28,7-37,1]), they had no first degree relatives with diabetes type two and none used 
any medications. Anthropometrical data are shown in table 3. 
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Protocol 
A crossover study was conducted, consisting of two separate 6 hours admissions, 
separated by a 1-week wash out period (Figure 5).  Subjects were randomly assigned 
to eat low glycemic or high glycemic test meals, simply by giving the first person on 
the list the first of the two test days the high glycemic lunch.  
 
Figure 5.  Study design. Each subject consumed either a low (meal L) or a high glycemic lunch (Meal H) the 
first day of study and switched to the other lunch the second day of study. At 5 pm both days the subjects ate 
the same type of ad libitum meal.  
The last two days before the test day, subjects were instructed not to engage in 
strenuous physical activities and to have a normal diet. At breakfast on the day of the 
test, a meal consisting of corn flakes and low fat milk was consumed. The amount 
consumed was the same both test days, and was determined by asking them to pour 
out an amount of corn flakes and amount of milk that they would usually eat. To 
ensure that caffeine withdrawal symptoms were avoided, an individually standardized 
drink for breakfast was consumed both test days. Thus, subjects who normally drink 
coffee or tea for breakfast did this also on test days. The subjects were instructed to 
terminate their breakfast before 8.30 a.m.  
The subjects were admitted to a hospital research laboratory (Diabeteslaboratoriet, 
Hormonlaboratoriet, Aker Universitetssykehus) at 11.30 a.m. Each day the subjects 
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were asked to fill out a food diary where they reported their food intake the two days 
preceding the day of the test, and at breakfast the day of the test. Only two subjects 
were studied per day, one received the high glycemic and the other the low glycemic 
lunch. The first and the last day of testing for the group as a whole were done within a 
timeframe of four months. Tuesdays and Thursdays were used as test days. At 11.55 
an intravenous line was placed, and the subjects were asked first at 11.58 and then 
every 30 minutes during 5 hours to record their hunger feeling on VAS. The VAS was 
a 100 mm line without partition, with at the left end `not at all hungry' (overhodet ikke 
sulten) and at the other end `extremely hungry' (ekstremt sulten). At 12 p.m. the test 
meal was consumed. The meal was eaten within 20 minutes. At 12 p.m., and then 
each half hour blood samples were obtained. During this part of the study, they were 
allowed to sit down, walk, but not to go out of the laboratory. Between 1 p.m. and 4 
p.m. the subjects were allowed to drink a maximum of 400 ml of water, but not more 
than 200 ml at once. After 5 hours the registration ended and the intravenous line was 
removed. The subjects then ate a casserole dish ad libitum. The subjects served 
themselves from a large bowl into a smaller bowl and consumed their meal in an 
unsupervised fashion. The large bowl was weighed before and after the meal, and the 
amount consumed was registered. The subjects were instructed to eat until they were 
comfortably full, but for no longer than 25 minutes. They were not told that their 
energy intake would be measured at this meal, only that we needed to obtain further 
data in the satiated state. A blood sample was obtained from a finger for measurement 
of the blood glucose. This measurement served no other purpose than concealing their 
food intake being measured. The subjects left the laboratory at 5.30 p.m. At the last 
day of testing the subjects were asked, using a form (see appendix G), if one of the 
lunch meals tasted appreciably better than the other, and how good the ad libitum 
meal tasted.  
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Test meals 
Two isoenergetic lunches (table 4), with different sensory and nutritional 
characteristics, were composed using combinations of common vegetables, lentils, 
potatoes and chicken.  
           
Meal composition based on a 2735 kJ portion Table 4 
Meal H Meal L 
   
Foods Potatoes 450 g Lentils 99 g 
 Chicken breast 83,3 g Chicken breast 83,3 g 
 Tomatoes 65 g Onion 200 g 
 Broccoli 90 g Broccoli 250 g 
 Olive oil 16 g Olive oil 14 g 
 Spinach 35 g Water 83 g 
 Maizena 18 g  
 Water 40 g  
    
Fibre 11,8 g  22,3 g 
Energy from carbohydrates 55,2 % 41,6 % 
Energy from protein 20,4 % 33,9 % 
Energy from fat 24,4 % 24,4 % 
Energy density 3,2 (kJ/g) 3,2 (kJ/g) 
Energy, % of estimated REE 28 % 28 % 
 
 
The ad libitum meal was a palatable casserole dish consisting of 35% fat, 25 % 
protein and 40 % carbohydrate (based on energy content). 
 
The Harris Benedict formula (125) was used for the calculation of REE (Resting energy 
expenditure)(in kJ): 
 
                        REE = 278 + 57,5 W + 20.92 H – 28,37 A 
  
W is weight in kilograms; A is age; H is height in centimetres.  
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Due to the relatively lower metabolic rate of fat mass than that of lean tissue, and the 
intrinsic limitations of using a formula for this estimation, using this formula does not 
provide exact values for predicted REE. However, it provided a means to standardize 
meal size among individuals of different body weight. 
Blood analysis 
Blood samples were analyzed with the following methods: plasma glucose was 
measured using a Beckman Glucose Analyzer 2 which determines plasma glucose by 
means of the oxygen rate method employing a Beckman Oxygen Electrode; serum 
insulin was measured using a competitive radio immuno assay kit from Linco 
Research Inc.; serum leptin was measured using a competitive radioimmuno assay kit 
from Linco Research Inc; serum ghrelin was measured using a competitive 
radioimmunoassay kit from Linco Research, serum growth hormone was measured 
using a non-competitive immunofluorumetric assay from AutoDELFIA. All 
measurements were done in duplicates, and were performed by the staff at the 
Hormone Laboratory at Aker Hospital.  
Data analysis 
Hormone and blood glucose concentrations are expressed as mean ± SD. Repeated 
measures analysis of variance was used to estimate the responses to the meals, using 
SPSS version 11. Incremental area under the curve values for glucose and insulin 
were calculated using the trapezoidal rule. For insulin and glucose, their respective p-
values refer to differences in IAUC between mean values. 
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4. Results 
Baseline values 
At baseline, mean or median serum glucose, insulin, growth hormone, leptin and 
ghrelin levels were not different between test days H  and L (the day meal H and L 
was consumed, respectively). There were also no differences in reported hunger 
(Table 5). 
          
Table 5. Baseline levels of glucose, hormones and hunger on the two test days (H and L). Hunger was 
evaluated using a 10 cm VAS-scale with ‘not at all hungry’ at the 0 cm end, and ‘extremely hungry’ at the 10 
cm end.  Values are expressed as mean ± Standard Deviation (SD), and  as median ± Inter Quartile Range 
(IQR).  
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Blood glucose concentration  
After meal H the glucose level rose to a peak of 8.4 mmol/l at 1 hour and returned to 
baseline values at approximately 2.5 hours (Fig 6). Thereafter the glucose 
concentration continued to decline, albeit more slowly, until measurements stopped 
five hours after the lunch meal. After meal L the glucose response was appreciably 
less as compared to meal H and rose to a peak of 6.2 mmol/l at 0.5 hours. Glucose 
levels were lower after meal L as measured by IAUC (104 vs. 249 mmol · l-1 · min; 
P=0.001). After about 2.5 hours glucose levels were the same on both regimens, but 
thereafter glucose declined more after meal H, being lower relative to meal L from 
210 min until measurements stopped at 300 min (P0.05). The lowest glucose value 
observed in an individual was 4.3 mmol/l after meal H (at 150 and 180 min) and 4.8 
mmoles/l after meal L (at 120 min). Baseline values were omitted in this comparison. 
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Figure 6.  Changes in plasma glucose levels from baseline after meal H (blue line) and meal L (Pink line) 
(Mean ± SD, n=11). Baseline values: H=5,6 ± 0.5 mmol/l; L=5.5 ± 0.4 mmol/l (Mean ± SD). 
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Serum insulin concentration 
After meal H serum insulin concentration increased to a peak at 1 hour and 
subsequently declined reaching baseline values after approximately 245 min (Fig. 7). 
After meal L, the insulin response was blunted, peaked at 1 hour, and declined 
relatively slowly throughout the remainder of the registration period. The average 
insulin concentration after meal L did not reach baseline values however. Insulin 
levels increased appreciably more after meal H as compared with meal L. From 
baseline, levels increased by 536 pmol/l to peak after meal H and by 137 pmol/l to 
peak after meal L, and the IAUC was 247 % larger after meal H vs. meal L (58.9 vs. 
23.8 pmol/l * min; P=0.007).  
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Figure 7.  Changes in serum insulin concentration from baseline after meal H (blue line) and meal L (Pink 
line) (Mean ± SD, n=11). Baseline values: H=106.4 ± 41.5 pmol/l; L= 91.5 ± 23.1 pmol/l (Mean ± SD). 
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Serum growth hormone concentration 
After meal H the response curve showed a modest decline during the first hours and 
thereafter increased to a peak at 240 min (Fig. 8). The shape of the response curve 
was similar after meal L, but the growth hormone levels did not increase further after 
returning to baseline levels. The entire curve was lower after meal L relative to meal 
H.  There was a significant time by meal interaction (P=0.036). Growth hormone 
levels tended to be higher at 270 min (P=0.059) after meal H and was significantly 
higher at 300 min (P=0.04) (Fig. 8).  
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Figure 8.  Changes in serum growth hormone concentration from baseline after meal H (blue line) and meal L 
(Pink line) (Mean ± SD, n=11). (One sample from one of the subjects is missing.) Baseline values: H=0.62 ± 
0.68 µg/l; L=1.12 ± 1.00 µg/l (Mean ± SD). 
  55 
 
Serum leptin concentration 
Leptin levels declined during the initial 30 min after meal H and then had, in general, 
a continuous increase throughout the remaining 4.5 hours of the observation period 
(Fig 9). After meal L the leptin level reached a nadir at 2 hours and remained 
approximately at this level the remaining 3 hours. There was a non-significant 
tendency to higher leptin levels after meal H (P= 0.136) (Fig. 9).  
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Figure 9. Changes in serum leptin concentration from baseline after meal H (blue line) and meal L (Pink line) 
(Mean ± SD, n=11). Baseline values: H=680.3 ± 319.8 pmol/l; L=693.1 ± 274.8 pmol/l (Mean ± SD). 
  56 
 
Serum ghrelin concentration 
Whereas ghrelin exhibited a flat curve during the entire 5 hour period after meal L 
(Fig 10), the ghrelin response curve was biphasic after meal H, with an initial decline 
from baseline at 1 hour, thereafter increasing to a peak at 270 min. There was a 
significant time by meal interaction (P= 0.027). Ghrelin levels were lower at 60 min 
(P=0.003), and higher at 270 min after meal H (P=0.047) relative to meal L. (Fig. 10).   
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Figure 10. Changes in serum ghrelin concentrations from baseline after meal H (blue line) and meal L (Pink 
line) (Mean ± SD, n=11). (One sample from one of the subjects is missing.) Baseline values: H=1195.0 ± 255.6 
µg/l; L=1232.5 ± 350.9 µg/l (Mean ± SD). 
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Reported hunger 
Reported hunger was lower 30 min after the lunch meal relative to baseline on both 
regimens (Fig 11). Thereafter hunger increased steadily and reached a peak at the last 
time of reporting before the 5 pm meal was to be consumed. At no time point was 
reported hunger different between meal L and H (P=0.985) (Fig. 11).                   
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Figure 11.  Changes from baseline in reported hunger after meal H (blue line) and meal L (Pink line) (Mean ± 
SD, n=11), as measured by VAS. Baseline values: H=4.97 ± 2.39 cm; L=5.40 ± 2.21 cm (Mean ± SD). 
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 Energy intake 
Energy intake at the second meal was 3665 kJ after the meal H and 3525 after meal L 
(Fig 12). Differences were not significant between meals (P=0.66).  
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                     Figure 12. Energy intake at the 5 p.m. meal after meal H and L (mean ± SD, n=11). 
 
Correlations 
There was a negative correlation between BMI and baseline values of ghrelin (r=-
0.727; P=0.011), a positive correlation between BMI and baseline leptin (r=0.748; 
P=0.008). There were no significant correlations between BMI and glucose (r= -
0.242; P=0.474), or BMI and insulin (r=-0.091; P=0.79).  
Palatability ratings 
Three subjects rated meal L to have appreciably better taste than meal H, while two 
subjects rated meal H to have appreciably better taste than meal L, and one subject 
rated meal H to have slightly better taste than meal L. Five subjects did not find that 
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one meal tasted better than the other. Two subjects found that the ad libitum meal had 
a taste that was on the poor end (less than 4) on the scale, while nine subjects found 
that the ad libitum meal had a taste that was on the good end (more than 3) on the 
scale. 
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5. Discussion 
It would seem from the present study that the research question 1) under “Objectives” 
(p. 40) can be answered with “yes”, whereas question 2) can be answered with “no”. 
Thus, there where differences in hormones known to affect appetite and food intake 
between meal H and L, but ad libitum food intake was not different on the two 
regimens, and the hunger scores showed a close concordance between the regimens 
during the entire five hour period. 
Although meals differing in glycemic effect have been questioned with regard to their 
insulin and glucose responses being different when eaten as the second meal(112), the 
present study showed that the glucose and insulin responses may differ by more than 
100% between two high carbohydrate meals, as measured by IAUC. Additionally, the 
glucose and insulin levels were remarkably stable after consuming the low glycemic 
lunch, with only small increases during the observation period. These results indicate 
that it is possible, simply by choosing another source of carbohydrate, to eat rather 
large amounts of carbohydrate with only a small subsequent increase in blood 
glucose. Also, at the end of the observation period there were differences in the level 
of hormones related to meal initiation and hunger, with levels of ghrelin and growth 
hormone being larger after the high glycemic meal.  
Ghrelin has consistently been shown to be transiently suppressed after meals(55,63,126), 
but it is unclear what factors related to the meal that induces this effect. In this study, 
we showed that postprandial ghrelin levels are related to meal composition factors 
which may include, but also go beyond the gross energy content of the meal. Whereas 
ghrelin was not different from baseline at any time after meal L, ghrelin showed a 
biphasic response after meal H. The finding that ghrelin levels under certain 
circumstances can be unaffected by a meal of normal size is, to the best of our 
knowledge, new, and may reflect the stability of the overall energy flux after the 
consumption of a low glycemic meal, by providing a slow and extended time of 
absorption of nutrients. Also, the fact that ghrelin levels did not increase at the end of 
  62 
the five hour observation period is somewhat surprising, based on the fact that ghrelin 
has been shown to increase before all of three meals during the day in a study with a 
similar meal pattern(63). These apparent discrepancies may suggest that the type of 
ingested nutrients, more than time elapsed since the last meal, is a major determinant 
of ghrelin levels on a short term basis, and that the rise in ghrelin levels, observed at 
the end of the observation period after the high glycemic meal, in some way may be 
related to overall energy flux.  Possible candidates that may mediate the relation 
between energy flux and ghrelin levels are insulin and/or glucose, which are observed 
to have reciprocal 24-h profiles when three normal meals are eaten during the day(63). 
Ghrelin levels also had reciprocal profiles with glucose and insulin levels in the 
present study. It is however not clear whether this pattern is a direct effect, or if it is 
mediated by other substances such as somatostatin, oxyntomodulin and PYY, which 
all have been shown to suppress ghrelin levels, and which all increase after meals (57-
59)
. Although differences in hunger or food intake were not related to changes from 
baseline ghrelin levels in this postprandial study, potential differences in ghrelin 
levels after consuming meals differing in glycemic effect may yield different 
responses on food intake and hunger under other circumstances, or the differences 
may be of potential long term importance in body weight control due to the orexigenic 
effects of ghrelin. 
Mean leptin levels were not significantly higher different between meal H and L. 
There are however indications from a previous study(46) that the leptin levels may 
become significantly different when consuming several meals with different glycemic 
effects throughout a 24 hour period. Additionally, in a five-week intervention, the 
expression of the ob-gene was lower on the low glycemic regimen vs. the high 
glycemic regimen(118). A lower level of leptin when consuming different diets have 
been interpreted by some to be an indicator of an increased risk of an increase in body 
weight(127). The finding that leptin infusion does not decrease food intake acutely in 
non-leptin deficient individuals, and that prolonged leptin infusion does not appear to 
lead to body fat loss in obese humans, questions the role of leptin in body weight 
regulation in the obese state. Rather, an increase in leptin postprandially seems to be 
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primarily mediated by an increased intracellular energy availability in adipocytes(128). 
Thus, reductions in leptin levels on a low glycemic diet may indicate that less 
amounts of nutrients are directed to adipose tissue.   
Methodological considerations 
There seems to be at least two possible explanations for the similar ad libitum energy 
intakes and hunger ratings after each of the test meals: 1) there is no difference in 
hunger or appetite after consuming meal H and L; or 2) hunger ratings and food intake 
are affected more by external cues than by actual hunger and appetite. It would appear 
that explanation number 1 does not comprise the entire picture, based on the observed 
differences in growth hormone, ghrelin and glucose levels at the end of the five hour 
period. First, the reduction in glucose levels below the fasting values, with 
concomitant increases in growth hormone, may indicate a perceived reduction in 
availability of fuels by the body and could thus induce hunger and increased 
appetite(86). Second, ghrelin is the strongest systemic, endogenous appetite enhancer 
known(50). In this study, postprandial growth hormone and ghrelin levels were higher 
after the high glycemic meal (after 270 minutes and 300 minutes, for ghrelin and 
growth hormone respectively), and glucose was lower on the high glycemic regimen 
during the last two hours of measurement. It is therefore tempting to suggest that 
reported hunger in this setting could be more regulated by external cues, such as the 
number of hunger scale forms completed, boredom, time of day etc, than actual 
hunger. A study by Toumisto et al(129) supports this contention. Similarly, food intake 
may also have been subject to influence by external cues.  
The way of measuring energy intake in this study may not be optimal for the detection 
of true appetite differences. First, the subjects’ energy intake was only recorded at a 
single meal, which was to be consumed within a limited amount of time. This may 
have limited the subjects’ possibility to “evaluate” if their energy needs were fulfilled. 
Second, the meal offered at the ad libitum meal was a one choice only. Therefore, 
subjects were not able to choose between foods that have different properties 
regarding palatability, energy density, sweetness or other factors that potentially could 
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have resulted in different energy intakes. Third, subjects were not able to eat when 
they were hungry and were forced to wait. This may have affected food intake, 
because in real life situations, food is generally easy accessible. Thus, the ad libitum 
meal in this study may not reflect the behavioural responses that would most likely 
occur under free-living conditions. The lack of effect on food intake is in keeping 
with some studies, and in conflict with others. Of five identified studies comparing 
mixed meals with differing glycemic effect and their effect on food intake, 
three(86,130,131) reported a statistically significant result in favour of the low glycemic 
meal, one(132) reported no difference between meals and one(133) reported a trend in 
favour of the high glycemic meal. The reasons for the differing results may in part be 
related to other aspects of the test meals than differences in glycemic effect. Only the 
study by Ludwig et al(86) appears to have kept possible confounding variables, such as 
energy density, macronutrient composition, palatability and fibre, constant between 
meals. When comparing the present study with the study by Ludwig et al(86) however, 
most of the possible confounding variables in the meals in the present study do not 
appear to play a significant role with regard to food intake. First, energy density was 
not different between meals and secondly, palatability was similar in the two meals.  
Thirdly, the difference in macronutrient composition in this study appears not to be 
large enough to affect appetite. Specifically, concerning the degree of difference in 
protein and carbohydrate content in this study, there is support for this not having a 
significant effect on appetite. In a study by Raben et al(134), where the difference in 
protein content and carbohydrate was larger between meals than in this study, no 
effect of protein or carbohydrate on hunger and food intake were observed. One 
factor which could play a role however, is the amount of available carbohydrate in the 
two major carbohydrate sources in each of the meals. Lentils consist of a minimum of 
10%(135) resistant starch, whereas potatoes consist of around 2%(136) resistant starch 
(based on total starch). Carbohydrate absorption was therefore probably appreciably 
less after meal L than after meal H, and could thus have affected hunger ratings and 
food intake. There are also other, non-meal composition factors, which can explain 
the discrepancy between the present study and the study by Ludwig et al(86). One such 
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factor could be the age of the subjects. It is possible that children are less affected by 
external cues than adults when it comes to choosing the amount to eat. Furthermore, 
the fact that the test meals were given as a second meal of the day in the present study 
could have affected the outcome. The possible mechanisms involved are not apparent 
however.  
Another factor is the amount of food served, either based on volume or energy 
content. The energy content of the test meals was 28% of estimated REE, which is 
larger than the 18.5% REE in the study by Ludwig et al(86). A few of the subjects that 
were served the largest amount of food for lunch (i.e. the subjects with the highest 
estimated REE), complained that the amount of food was larger than what was needed 
to feel full, and one person informed that he struggled to eat all of the food he was 
served. This could possibly have affected hunger ratings, and food intake at the ad 
libitum meal. However, we did not collect information to quantify this aspect in an 
exact manner. Therefore it is hard to evaluate what effects, if any, this had. It is 
however possible that the amount of food was so large in this study that the subjects 
felt overfed on both regimens, and thus the test meals may not reflect normal meal to 
meal behaviour. Also, ingesting amounts of food which go beyond what is perceived 
as pleasant, may not reflect usual meal to meal metabolism. In particular, the large 
amount of food may have overridden the proposed mechanisms in the study by 
Ludwig et al(86), i.e. that high glycemic meals subsequently render the body in a 
temporary limited access to metabolic fuels, and thus exacerbate appetite. The 
mechanism for a potential override effect remains elusive.  
Another difference between the study by Ludwig et al(86) and our study is related to 
specific foods used. The foods most likely to be the more relevant in meal H and L 
would seem to be lentils and potatoes, as these were the major components of the 
meals, as measured by weight. Although potatoes yield a relatively high glycemic 
response, the potato may have other properties which could counteract the effects 
related to the glycemic response, with regard to hunger and food intake. One such 
property could be the fibre content. Potatoes contain a considerable amount of fibre, 
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but it is unlikely that this affected the results, because in other studies, fibre, both 
fermentable and non-fermentable, has not been shown to have appetite reducing 
properties (137). The potato also contains other substances than those mentioned here, 
but it remains to be investigated what potential effects these substances could have on 
hunger. 
The number of subjects was not large. Thus, the study could have been underpowered 
with regard to some of the variables. For instance, given the standard deviation 
observed in this study, a difference of 1880 kJ (53%) at the ad libitum meal would 
have been needed to detect significant differences.    
The subjects’ diet and physical activity level during the days prior to study could have 
affected the results, both due to the fact that the subjects’ diet and physical activity 
level were self reported and the fact that the diet and physical activity instructions 
were quite general. 
One of the subjects informed that he found the intravenous catheter to be very 
uncomfortable and that thoughts about hunger or eating were rather hard to quantify 
as his thoughts were appreciably more concerned with the intravenous catheter than 
with food. A post hoc analysis where this subject was excluded, did not change the 
results with regard to hunger and food intake. 
The difference in glucose and insulin response between the two regimens is larger 
when evaluated as IAUC than AUC. There are reasons that IAUC was chosen as a 
measure of insulin and glucose response in this particular study. The major hypothesis 
was that increments in postprandial blood glucose would set a cascade in motion, as 
described earlier, which would lead to increased hunger and food intake. Furthermore, 
low levels of blood glucose are probably most often seen, in non-insulin dependent 
individuals, after the consumption of foods which give an initial large increment in 
blood glucose (138). Thus, if hypoglycaemia is prolonged for a long enough time after 
hyperglycemia, measuring AUC could nil out the initial hyperglycemia. Similarly, 
insulin increments bear more relevance to the hypothesis than AUCs, because a high 
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level of insulin, rather than a low one, is what is considered important in the 
regulation of hunger and food intake. Additionally, with regard to other effects of 
oscillations in blood glucose and insulin within the normal range observed in healthy 
individuals, high levels of these variables are viewed as more important as causes of 
pathologic states than are low levels. 
This study sought to elucidate one particular mechanism related to obesity 
development. The inclusion of overweight and obese people in the study which have 
metabolic derangements as a cause of their high BMI was thus considered important. 
It does however appear that the classification of overweight and obesity based on 
BMI may not be the best proxy for the increased health risk associated with higher fat 
mass, because a large subset of individuals with a BMI over 25 do not have an 
increased health risk. Thus, their higher than average BMI may be largely set by 
genetics and less by metabolic derangements. 
In general, the reason for the discrepancy between studies on meals with different 
glycemic effects that have found differences in hunger, and those that have not, need 
further investigation 
Perspectives 
As alluded to in the introduction, regulation of body weight is complex. An 
individual’s attempt at interfering with this regulation by eating less than the body 
demands, i.e. less than what fulfils hunger, is seldom successful in the long term. 
Thus, the understanding of what factors cause hunger to increase beyond the 
maintenance of normal body fat stores, is what seems to herald further insights into 
the etiology of obesity. Recent advancements linked to the discovery of several 
hormones that affect body weight, body composition, food intake and hunger have 
increased this understanding, and indicate that a range of factors and systems 
powerfully act to impede an individual’s attempt at reducing body weight. Thus, how 
these hormones relate to differences in diet, physical activity and other factors, seem 
to be one area of investigation which may play a major role in the understanding of 
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obesity development. In this study we have shown that a low glycemic meal relative 
to a high glycemic one is associated with different short term alterations in the 
concentration of hormones believed to be central in long term body weight regulation. 
To what extent these acute differences are significant in long term body weight 
regulation remains to be further explored. 
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6. Conclusion 
High carbohydrate meals, containing carbohydrates from different sources, can differ 
greatly in their postprandial glycemic effect, as well as in their influence on hormones 
known to be involved in appetite regulation. Yet, such differing meals may not 
influence hunger and food intake, as evaluated by VAS during the next five hours, 
and by ad libitum food intake at the next meal, in overweight men. 
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Etternavn, fornavn  
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professor 
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0318 
 
Poststed: 
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Medarbeidere (navn, tittel, stilling, arbeidssted): 
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Ved studentprosjekter oppgis navn på den student som skal gjennomføre prosjektet: 
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Internasjonal multisenterstudie   
 
 
3. Oppdragsgiver 
Fullstendig navn: 
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Faks: 
- 
Kontaktperson: 
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4. Prosjektbeskrivelse 
Prosjektbeskrivelsen må gis en alminnelig og forståelig språkform på norsk. Det må redegjøres kort for hensikt, hypotese, metode, tidsrom 
og prinsipper for utvelgelse av forsøkspersoner/informanter og aldersgrupper. Det er ikke tilstrekkelig å henvise til protokoll. Forsøksprotokoll 
og evt spørreskjemaer etc skal vedlegges. 
 
Introduksjon/problemstilling: Glykemisk indeks er et mål på karbohydratholdige matvarers evne til å 
øke blodsukkeret. Forskning i løpet av de siste 20 årene har vist at begrepet kan være et nyttig verktøy i 
behandling og forebygging av livsstilssykdommer, spesielt diabetes og overvekt. Imidlertid kreves det 
mer forskning og sikrere kunnskap. I Norge har det ikke vært gjort studier på sammenhengen mellom 
sykelighet og GI. Denne studien tar utgangspunkt i norske forhold og tar sikte på å bidra med ny viten 
til dette forskningsfeltet.  
 
 Inntak av måltider med høy glykemisk indeks gir høy blodsukkerstigning og sterk insulinrespons. 
Hypotesen er at disse effektene, via til dels uklare mekanismer, fører til økt sultfølelse og overspising.  
 
Med dette som bakgrunn har studien som mål å teste effekten av et høy- vs et lav-glykemisk-indeks- 
måltid på variabler som har med energiomsetning og energiinntak å gjøre. Mer spesifikt vil det vurderes 
om et høy-GI-måltid fører til økt frivillig energiinntak 5 timer etter testmåltidet, og om denne eventuelle 
forskjellen kan forklares ut i fra endringer i blodglukose, insulin og adrenalin.   
 
 
Studiedesign: 12 overvektige deltar i en crossoverstudie, hvor to måltider med henholdssvis høy og lav 
GI-mat testes på hver forsøksperson med en ukes mellomrom. De to testmåltidene er gjort så like som 
mulig med unntak av hovedkarbohydratkilden: I høy-GI-måltidet benyttes poteter, mens det i lav-GI-
måltidet benyttes linser. Det legges vekt på at det er to reelle måltider som testes, i betydningen at 
resultatet er godt overførbart til nordmenns faktiske kosthold. Testmåltidene inntas kl 12,  blodprøver 
tas og sultfølelse registreres umiddelbart før og hver halvtime etter testmåltidet frem til det har gått 5 
timer. Et ad libitum måltid innntas 5 timer etter testmåltidet, hvor energiinntak registreres. Det benyttes 
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venøst kateter for måling av hormoner, og kapillærblod fra fingerrtupp for måling av blodglukose. 
Forsøkspersonen forlater forsøkslokalet kl 17.45.  To og to forsøkspersoner testes på samme dag slik at 
det totalt blir gjennomført 12 testdager. 
 
Målinger: Glukose i blod,  og hormonene: insulin, veksthormon, noradrenalin og adrenalin      
 
Laboratorium/Framdriftsplan/Økonomi etc.: Avdelingsoverlege dr. med. Kåre I. Birkeland stiller 
Hormonlaboratoriets lokaler på Aker sykehus til disposisjon for gjennomføring av selve forsøket. 
 
Prosjektet ble påbegynt i august 2001. Førsøket gjennomføres oktober 2002 - desember 2002, og 
databearbeiding og rapportskriving gjøres våren 2003.  
 
Første forsøksdag er satt til å være 15. oktober, og forsøket vil foregå på tirsdager og torsdager fram til 
og med 5. desember.  
 
Prinsipper for utvelgelse av forsøkspersoner og aldersgrupper:  
 
Denne typen mateffektstudier burde gjøres for representative grupper av hele befolkningen. Imidlertid 
er ressursene i dette forsøket begrensede. Dessuten er forskningsfeltet såpass nytt at det gjelder å 
maksimere så mange faktorer som mulig for å avgjøre om videre forsøk er nødvendig på flere grupper 
av befolkningen. Det antas at overvektige vil ha de klareste effektene av de ulike måltidene. Da alder 
kan påvirke en rekke fysiologiske variabler, er aldersspennet begrenset.    
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5. Vitenskapelig vurdering 
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Studier skal gjennomføres i henhold til god vitenskapelig standard, når det gjelder formål, nytte, viktighet, relevans og metode.  Metodevalg, 
fremgangsmåte og effektmål må begrunnes.  
 
Bakgrunn/formål: Nyere forskning tyder på at langvarig økning i mengde blodsukker i de første timene 
etter matinntak disponerer for utvikling av viktige folkesykdommer/tilstander som fedme, 
insulinresistens, type-2-diabetes og hjerte- og karsykdommer, men vi har liten kunnskap om i hvilken 
grad norsk mat med ulik glykemisk indeks påvirker disse helsevariablene. Det er derfor viktig å 
fremskaffe ny kunnskap om postprandiale responser. Kunnskapen om hvordan forskjellige matvarer 
påvirker sukkermengden i blodet de nærmeste timene etter et måltid, er dessverre tildels svært 
mangelfull. Prosjektet tar sikte på å systematisk undersøke postprandiale responser. 
 
Nytte/viktighet: Det er økende dokumentasjon på at høy og langvarig økning i blodsukker etter måltider 
dosponerer for store folkesykdommer i Norge og andre vestlige land. Studien antas derfor å ha en 
betydelig nytteverdi fordi den framskaffer kunnskaper som kan hjelpe både den enkelte forbruker, 
matvareprodusenter og myndighetene når det gjelder valg, tilbud og anbefaling av matvarer.  
 
Valg av metode: Det er nødvendig at studien gjøres på mennesker, pga kvalitative og kvantitaive 
forskjeller i matresponser mellom mennesker og dyr.  Effektmål er sultfølelse, arealet under 
glukosekurven, frivillig matinntak og insulin- og adrenalinrespons. Disse effektmål er valgt pga at høye 
postprandiale blodsukkerverdier har vist seg å være assosiert med sykdom, og pga at disse effektmål 
samlet kan gi forklaringer på hvorfor høy glykemisk indeks mat gir eventuell overspising.  
 
Gjennomførbarhet: Prosjektet forutsetter finansiering, forsøkspersoner, laboratoriefasiliteter og 
vitenskapelig og teknisk ekspertise. Legat for fremme av hygienisk forskning bidrar med økonomisk 
støtte, dessuten er matvareprodusenten Helios interessert i å støtte prosjektet. Forsøkspersonene vil bli 
rekruttert fra Statens Vegvesen i Oslo og/eller fra Helios. Laboratoriemetodene er rutine ved de steder de 
utføres: Aker sykehus og Ullevål sykehus. 
 
STATISTIKK:  Effektmål for de nevnte  variabler vil være arealet under kurven (AUC), evt. peak, time-
to peak (nadir) eller slope. Forskjeller mellom grupper vil estimeres med Students t-test. Antallet 
forsøkspersoner er bestemt etter gjennomgang av litteratur vedrørende tilsvarende forsøk, da det ikke er 
tid og ressurser nok til å gjøre en særskilt pilotstudie (hovedfagsoppgave for Inge Lindseth) 
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6. Inklusjon av begge kjønn 
Studier må dimensjoneres slik at det kan gjøres kjønnsspesifikke analyser av resultatene. Dersom ikke begge kjønn inkluderes, må dette 
begrunnes. Ved inklusjon av fertile kvinner skal det redegjøres for evt bruk av prevensjon og prosedyrer ved uforutsett graviditet. Ved 
inklusjon av gravide må prosjektleder vurdere og beskrive mulige konsekvenser for kvinnen og for fosteret og redegjøre for hvilken 
oppfølging som er planlagt.  
 
Kun menn vil bli inkludert i studien, da menstruasjonsyklus kan påvirke resultatene, og det er ikke 
kapsitet til å gjøre studien på begge kjønn. 
 
 
  
7. Klassifisering (hvis aktuelt, kryss av for mer enn én): 
Prosjektet er: 
 
 Grunnforskning  
 
 Klinisk, anvendt  forskning  
 
 Bio- og genteknologisk forskning   
 
 Utprøving av medisinsk utstyr  
 
 Legemiddelutprøving  
 
    Utprøvningsfase:  I   II   III   IV  
 
 Samfunnsmed./epidemiol. forskning  
 
 Psykologisk forskning  
 
  (Annen) samfunnsvitensk.  forskning  
 
 
Prosjektet er: 
 
 Terapeutisk  
 
 Ikke-terapeutisk  
 Prosjektet omfatter: 
 
 Allerede registrerte data  
 
 Friske personer  
 
 Pasienter/syke    
 
 Voksne  
 
 Barn (under 18 år)         
 
 Andre umyndige:        
 
 Kun kvinner/piker   
 
 Kun menn/gutter  
 
 Innsatte i fengsel  
 
 Soldater   
 
 Minoritetsgrupper   
 
 Personer med redusert kompetanse  
for informert samtykke  
 
 Fostre  
 
 Lik  
 
 Kun annet humant materiale  
 
    Hvilken type:        
 
 
 
Begrunn antall forsøkspersoner/informanter. Når det er relevant, gjør rede for styrkeberegning. 
 
Antall: 12. Dette anses som tilstrekkelig ut i fra lignende studier som er gjort. Jamfør særlig referanse nr 
4 i prosjektbeskrivelsen. 
 
 
  
8. Informasjon 
Redegjør for hvordan forsøkspersonene/informantene rekrutteres og gis informasjon om prosjektet, dets formål, eventuelle risiki, rett til å 
avbryte o.a. (Skriftlig informasjon til forsøkspersoner, evt. annonser, brosjyrer, samt samtykkeerklæring skal vedlegges. Dersom bare muntlig 
samtykke innhentes, må dette begrunnes særskilt. Dersom forsøkspersonene omfatter mindreårige, umyndige og/eller andre som ikke kan gi 
bindende samtykke, må det begrunnes hvorfor disse skal inkluderes. Hvis samtykke ikke kan ivaretas, må det gis en utfyllende begrunnelse 
for hvorfor prosjektet anses etisk forsvarlig å gjennomføre). 
 
Forsøkpersonene rekrutteres gjennom oppslag på arbeidsplass (vedlegg). 
 
 
 
 
 
9. Etisk vurdering 
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Drøft etiske spørsmål som prosjektet reiser. Angi spesielt hvilke etiske betenkeligheter det er ved prosjektet og begrunn eventuelt hvorfor man 
kan se bort fra dem eller hvordan man kan redusere betydningen av dem. 
 
Blodprøvetaking vil medføre smerter/ubehag, spesielt ved gjentatt taking av kapillærblod  fra fingertupp. 
Ubehaget vil imidlertid være av kort varighet. Denne typen blodprøvetaking er rutine ved sykehus og  
anses å innebære  liten risiko.  Deltakelse i prosjektet kan på den annen side gi verdifull informasjon til 
den enkelte. Dels får vedkommende greie på eventuelle forhøyete fasteverdier av blodsukker, og får 
derfor muligheten til å behandle (ved kostomlegging eller medikamenter) sin tilstand. Derved bedres 
sjansene til å unngå sykdom pga forhøyete verdier. I tillegg får forsøkspersonene vite sin egen 
matrespons hva angår økning i blodsukker og endringer i ulike hormoner de nærmeste timene etter 
måltidet (fasteverdien av glukose kan være 'normal', mens postprandial glykemi er forsterket), noe som 
også kan gi grunnlag for forebyggende tiltak. Noen kan kanskje også oppfatte gratis måltid som en fordel.  
Forsøkspersonene bidrar dessuten til å frembringe verdifull informasjon for den generelle befolkning, for 
helsemyndigheter, og for matvareprodusenter. 
 
Om patologiske blodverdier oppdages vil vedkommende bli henvist til sin fastlege for oppfølging. Falske 
positive og negative funn vil være et problem for forsøkspersonene. Det antas at falske positive og 
negative funn er sjeldne.   
 
Vil prosjektet bli utført i henhold til retningslinjene i Helsinki-deklarasjonen eller andre relevante etiske retningslinjer? Hvis disse på noe punkt 
ikke følges, må dette begrunnes. 
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10. Prosjektleders forhold til forsøkspersonene/informantene 
Redegjør for prosjektlederens forhold til forsøkspersonene/informantene (f.eks. lege/pasient, lærer/student, overordnet/underordnet) 
 
Prosjektlederen er professor ved Universitetet i Oslo. Forsøkspersoner rekrutteres fra instanser som ikke 
har direkte tilknytning til UiO.  
 
 
 
 
 
11. Legemiddelutprøving 
• Redegjør for utførte og planlagte studier og for hvor mange pasienter som er inkludert i tidligere faser av utprøvingen 
• Grunngi dosevalg av studiepreparatet 
• Grunngi valg av sammenligningspreparat og dosering av dette i forhold til studiepreparatet. Hvis sammenligningspreparatet er et annet 
enn standard behandling, må det begrunnes særskilt. 
• Grunngi evt. hvorfor pasienter må tas av velregulert behandling 
• Grunngi bruk av placebo  
 
      
 
 
  
97 
 
 
 
12. Risiko 
• Redegjør for risiki, som f.eks. smerter, ubehag, psykiske påkjenninger, uhell, komplikasjoner, og for tiltak for å minske/forebygge disse. 
• Redegjør for om metodene er klinisk etablert eller ikke. Hvis de er nye, hvordan har prosjektleder og medarbeidere tilegnet seg klinisk 
erfaring med dem? 
•      På hvilket grunnlag er risiko vurdert? (dyreforsøk, pilotstudie, klinisk erfaring, etc.) 
•      Beskriv hvordan komplikasjoner, bivirkninger, uventede hendelser, nye toksiske funn etc blir registrert  
 
Den blodprøvetaking som benyttes er rutine ved sykehus, og anses å innebære liten risiko. 
Blodprøvetaking vil medføre smerter/ubehag av varierende grad, spesielt ved gjentatt prøvetaking. Hvis 
forsøkspersonen inviteres til å komme igjen flere ganger, vil vi vanligvis  la det gå ca en måned mellom 
hvert forsøk. Inntak av selve måltidet antas ikke å medføre ubehag. Om så viser seg å bli tilfellet, kan 
forsøkspersonen trekke seg, ihht samtykkeerklæringen.  
 
 
 
 
 
 
13. Forsikring 
Forsøkspersonene/informantene er dekket av følgende forsikring ved eventuelle uhell eller komplikasjoner: 
Pasientskadeerstatningsordningen  
 
Produktansvarsloven  
 
Særskilt forsikring  
 
Forsikring ikke aktuelt  (må begrunnes) 
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14. Beredskap 
Redegjør for beredskap for oppfølging dersom grunnlaget for studien endres underveis, så som ved økt risiko, uventede hendelser, nye 
og/eller mer alvorlige bivirkninger. Drøft evt. behovet for interimsanalyse og mulige tiltak, så som bruk av stoppgruppe, endring av design, 
endret informasjon til pasienter etc. 
 
Henvisning til fastlege dersom det oppdages patologiske verdier. 
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15. Honorering av forsøkspersoner/informanter og prosjektleder/medarbeidere 
Redegjør for eventuell honorering/kompensasjon for forsøkspersonene/informantene 
 
Hver forsøksperson vil få en godtgjørelse på 200 kr, samt dekning av reiseutgifter. Dessuten blir alle 
forsøkspersoner tilbudt en gratis kostholdsrelatert helsesjekk  
 
 
 
 
 
Redegjør for økonomiske ytelser til prosjektleder og medarbeidere fra farmasøytisk industri eller utstyrsleverandører i forbindelse med 
planlegging og gjennomføring av prosjektet. Redegjør også for evt interessekonflikter for prosjektleder.  
 
Det er søkt om støtte fra Helios, som er en matvareprodusent.  
 
 
 
 
  
 
16. Vurdering/godkjenning av andre instanser 
Komiteen minner om at noen prosjekter også skal vurderes/godkjennes av eller meldes til andre instanser (evt. uttalelser vedlegges eller 
ettersendes): 
                                                                                                Er søkt/meldt         Er vurdert/godkjent av         Er ikke aktuelt 
- Statens legemiddelverk        
 
- Datatilsynet    
 
- Norsk samfunnsvitenskapelig datatjeneste        
 
- Sosial- og helsedepartementet        
 
- Statens helsetilsyn     
 
- Andre:           
 
 
 
 
 
 
17. Publisering og sluttrapport 
Vil prosjektleder publisere eller gjøre allment tilgjengelig negative så vel som positive resultater, i henhold til Helsinkideklarasjon? Dersom 
svaret er nei, må dette begrunnes særskilt.  
 
 
Resultatene vil søkes offentliggjort etter beste evne. Et ønske er å få resultatene publisert i American 
Journal of Clinical Nutrition. 
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Forplikter prosjektleder seg til å sende inn melding til Regional komité for medisinsk forskningsetikk når prosjektet er avsluttet eller når det 
ikke blir sluttført?  Ved legemiddelutprøvinger er det tilstrekkelig at sluttrapport sendes Statens legemiddelverk.  
 
ja 
 
 
 
 
 
Det forutsettes at et prosjekt forelegges komitéen på nytt, dersom det: 
A)  under gjennomføringen oppstår uforutsette komplikasjoner, 
B)  blir gjennomført endringer i de forutsetninger som komitéen har basert sin avgjørelse på, f.eks. skifte av prosjektleder. 
 
 
 
Underskrift 
Sted: 
      
 
 Dato: 
      
Prosjektleders underskrift: 
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Appendix B: Information to test subjects 
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INFORMASJONSSKRIV TIL FORSØKSPERSONER 
 
24.10.02
 
Kan du tenke deg å delta i et matforsøk for å finne ut mer om hvordan 
sukker og hormoner i blodet øker de nærmeste timene etter ulike typer 
måltider? Og hvordan dette påvirker matinntaket? 
 
Vi ønsker å vite mer om dette fordi nyere forskning tyder på at sterk økning i blodsukker i de 
første timene etter matinntak kan disponere  for utvikling av fedme, sukkersyke og hjerte- og 
karsykdommer. Måltidseffekten kan variere fra en person til en annen, og bero på hvor mye vi 
spiser, type mat og tilberedning.  Prosjektet tar sikte på å undersøke i hvilken grad  inntak av 
forskjellige typer mat påvirker sukker- og hormonmengden i blodet de nærmeste timer etter 
måltidet, og hvordan dette igjen virker inn på matinntaket. Det benyttes vanlige porsjoner av 
mat beregnet for den alminnelige befolkning. 
 
Du kan melde deg som deltaker dersom du er mann mellom 20 og 70 år og er frisk. Denne 
gang er vi interessert i å rekruttere overvektige forsøkspersoner. Meld deg gjerne selv om du 
er i tvil om du vil bli regnet som overvektig eller ikke. Du kan ikke bruke nikotinholdige 
produkter forsøksdagen og du kan ikke innta alkohol de siste 48 timene før forsøket.  
 
Noen dager før forsøket må du gjennomgå en blodsukkerbelastingstest og svare på spørsmål 
om din helse. Dette vil ta i overkant av 2 timer. 
 
Selve forsøket:   
 
Prosjektet gjennomføres på Hormonlaboratoriet på Aker Sykehus. Det vil bli gjennomført to 
testdager per person. Du må møte kl 11.30, og forsøket blir avsluttet kl 17.45.  Dagene før 
testingen må forsøkspersonene ha en ’normal’ kost og ’normal’ fysisk aktivitet.   
 
Matforsøket foregår slik: To personer møter fastende kl 11.45. Kl 12 inntar de vanlige 
porsjoner av en lunsjrett i løpet av 20 min. Før matinntak, og hver halvtime i 5 timer tas en 
bloddråpe fra fingertupp eller øreflipp for måling av blodsukker. Ved de samme tidspunkter 
gjøres det også hormonmålinger fra venøst blod. Blodprøvene vil bli tatt via innlagt veneflon i 
armen. Under testingen må ikke forsøkspersonene spise annen mat eller være i sterk fysisk 
aktivitet, men  kan sitte og lese/gjøre arbeid.  
 
Blodprøvene blir tatt av trenet personell. 
 
Ulemper ved deltakelse 
Testdagen kan bli lang. Blodprøvetaking kan medføre noe smerter/ubehag, spesielt ved 
gjentatt taking av blod  fra fingertupp/øreflipp. Ved blodprøvetaking i arm kan det eventuelt 
komme en bloduttredelse som er helt ufarlig.  
 
Du kan når som helst trekke deg fra deltakelse i studien uten å oppgi grunn. Det vil bli gitt en 
økonomisk kompensasjon på kr 200.- pr person, og reiseutgifter vil bli dekket. Dessuten vil 
du bli tilbudt en gratis kostholdsrelatert helsesjekk med rådgivning hos ernæringsfysiolog.  
 
Fordeler med å delta i prosjektet: 
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Deltakelse i prosjektet kan på den annen side gi verdifull informasjon til forsøkspersonen. 
Dels får du greie på eventuelle forhøyete fasteverdier av blodsukker, og får derfor muligheten 
til tidlig behandling (ved kostomlegging eller medikamenter). Derved bedres sjansene til å 
unngå sykdom pga forhøyete sukkerverdier i blodet. I tillegg får du greie på din egen reaksjon 
mht økning i blodsukker og hormoner de nærmeste timene etter et måltid (fasteverdien av 
sukker kan være normal, mens mateffekten er forsterket), noe som også kan gi grunnlag for 
forebyggende tiltak.  Forsøkspersonene bidrar dessuten til å fremskaffe  generell nyttig 
informasjon om matens virkninger. Om det oppdages høye blodverdier, vil du bli rådet  til å 
kontakte fastlegen din. 
 
Matforsøket gjennomføres etter at det er tilrådd fra regional etisk komite. Innhentede data om 
forsøkspersonene, samt resultater av testene, vil bli behandlet konfidensielt. Ved publisering 
vil resultatene anonymiseres. Forsøkspersonene vil få tilgang til sine egne resultater. 
 
Vennligst undertegn nedenfor dersom du er villig til å være med i matforsøket. Kryss av for 
hvilken ukedag som passer best for deg. 
 
 
----------------------------------------------------------------------------------------------------------------- 
                                    SAMTYKKE OM DELTAKELSE 
 
Jeg har lest gjennom “Informasjonsskriv til forsøkspersoner” og gjort meg kjent med 
innholdet. Jeg ønsker å delta og er klar over hva prosjektet innebærer. Prosjektet er frivillig og 
det er mulig å trekke seg når som helst uten å oppgi årsak. 
 
 
Navn (blokkbokstaver):__________________________________________________ 
 
Underskrift:____________________________________________________________ 
 
 
For meg passer det best: Tirsdager   _____ 
                                        Torsdager   ______ 
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Appendix C: Self reported declaration of health status 
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Egenerklæring  til  legen 
 
Navn:  ____________________________________________________ 
 
Adresse: ____________________________________________________ 
 
Tlf.nr.:____________________ _____ Mobil tlf. Nr.:____________________ 
 
Fødselsdato: ____________________________________________________ 
 
Initialer:________________________________________________________ 
 
Sivil Status: ____________________________________________________ 
 
Utdannelse: ____________________________________________________ 
 
Yrke:  ____________________________________________________ 
 
 
 
 
Sykdom i familien 
 
Forekommer hjerte-karsykdom (dvs. hjerteinfarkt, brystkrampe, hjerneslag) eller høyt 
blodtrykk hos foreldre, søsken besteforeldre eller foreldres søsken oppstått i en alder 
under 65 år: (Sett ring rundt) 
 
     Hvis Ja, angi hvem: ___________________ 
   
JA  NEI     ___________________ 
 
Forekommer ellers noen av andre sykdommer i din familie, (Sett ring rundt) 
  
 
1.   Mage-/tarmsykdommer   Mor Far Søsken/besteforeldre 
 
2. Allergi/astma/lungesykdom  Mor Far Søsken/besteforeldre 
 
3. Nerve eller muskelsykdom  Mor Far Søsken/besteforeldre 
 
4. Sukkersyke    Mor Far Søsken/besteforeldre 
 
5. Annen sykdom    Mor Far Søsken/besteforeldre 
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Er noen av dine foreldre eller søsken bortgått?      Ja        Nei 
   
Angi i så fall hvem, i hvilken alder og dødsårsak:  
   
 ______________________________________________________ 
   
 ______________________________________________________ 
   
 
Kommentar til punktene/evt. snakk med legen 
   
 ______________________________________________________ 
  
 ______________________________________________________ 
   
   
Livsstil 
   
Røker du?  Ja Nei  Aldri røkt Av og til røker       Eks-røker 
 
Bruker du snus? Ja Nei 
 
        For røkere:          Gjennomsnittlig sigarettforbruk pr dag: ____________ 
   
 For eks-røkere: Hvor mange år hadde du røkt: ______  år.  Hva var ditt gjen- 
nomsnittlige forbruk pr. dag:  ______  sigaretter. 
   
 
   
Hvor mange kopper kaffe drikker du vanligvis i løpet av en dag? (Sett ring rundt) 
   
0     1-2  2-5  6-10  mer 
   
Hvor mange enheter* med alkohol drikker du vanligvis i løpet av 14 dager  
(Angi mengder for to typiske uker i løpet av siste halvår) ?  ___________ enheter. 
   
 *1 enhet = ½  (0,33 l) flaske pils eller 1 glass rødvin eller 1 dram/drink. 
   
   
 
Har du i løpet av siste år drevet regelmessig trening/fysisk aktivitet? 
 
 Ja      Nei  Hvis ja, hvor mange ganger pr.uke: _________ 
  
Vil du karakterisere din fysiske form som (Sett ring rundt) 
 
Meget god     God  Middels  Dårlig 
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Helse 
 
Nedenfor nevnes noen vanlige helseplager.  Alle punkt skal besvares. 
 
0: Ikke plaget        1: Litt plaget 2: En del plaget       3: Alvorlig 
 
  
Siste år Tidligere Kommentar 
1 Forkjølelse    
2 Hoste    
3 Svimmelhet    
4 Hodepine    
5 Bevegelsessyke (bil, fly, båt)    
6 Vondt i nakke    
7 Vondt i rygg    
8 Smerter i armer, skuldre    
9 Dovenhet i armer/ben    
10 Hjertebank, “ekstraslag”    
11 Brystsmerter    
12 Pustevansker    
13 Smerter i bena ved anstrengelser    
14 Sure oppstøt, “halsbrann”    
15 Sug eller svie i magen    
16 Magekatarr    
17 Mageknipe    
18 “Luftplager”    
19 Løs avføring, diaré    
20 Forstoppelse    
21 Hetetokter    
22 Søvnproblemer    
23 Tretthet    
24 Angst    
25 Nedtrykthet, depresjon    
26 Andre plager, hvilke?    
27 Tannsmerter    
28 Andre helseplager    
 
 
   
 
 
 Har du oppsøkt lege, fått behandling for noen av disse plager? Hvis ja, presiser: 
 
___________________________________________________________________________ 
 
___________________________________________________________________________ 
 
___________________________________________________________________________ 
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___________________________________________________________________________ 
 
___________________________________________________________________________ 
 
Har du vært innlagt på sykehus?             Ja       Nei 
  
       Hvor mange ganger? _______ 
  
       Angi årstall, hva du ble behandlet for, hvilket sykehus og hvor lenge du var der : 
 
Årstall: Behandlet for:  Sykehusets navn:      Oppholdets varighet 
   
______ ____________ ______________      _________________ 
   
______ ____________ ______________      _________________ 
   
______ ____________ ______________      _________________ 
 
Medikamenter (skal besvares) 
   
Har du i kortere eller lengre tid brukt medikamenter (også naturmedisin) i løpet av 
siste året? 
   Ja      Nei  Hvis ja, mot hva, og hvilken type og varighet: 
 
___________________________________________________________________ 
 
___________________________________________________________________ 
 
 
Bruker du faste medikamenter (også naturmedisin) ? 
   
   Ja      Nei  Hvis ja, mot hva, og hvilken type og varighet: 
 
 ____________________________________________________________________ 
 
____________________________________________________________________ 
 
Oppsummering: 
    
Gi en kort beskrivelse av din nåværende helsetilstand: 
 
__________________________________________________________________________ 
 
__________________________________________________________________________ 
 
__________________________________________________________________________ 
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Tilleggsopplysninger: 
 
___________________________________________________________________________ 
 
___________________________________________________________________________ 
 
___________________________________________________________________________ 
 
___________________________________________________________________________ 
 
___________________________________________________________________________ 
 
___________________________________________________________________________ 
 
___________________________________________________________________________ 
 
___________________________________________________________________________ 
 
___________________________________________________________________________ 
 
___________________________________________________________________________ 
 
___________________________________________________________________________ 
 
___________________________________________________________________________ 
 
___________________________________________________________________________ 
 
___________________________________________________________________________ 
 
___________________________________________________________________________ 
 
___________________________________________________________________________ 
 
Jeg erklærer herved at jeg har besvart spørsmålene sannferdig og etter beste vitende: 
 
 
Sted:  ____________________________ Dato:  ____________________________ 
 
 
     Underskrift:  _______________________________________ 
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Vedlegg 
Kostholdsanbefaling to dager før forsøksdagen 
 
Forslaget er hentet fra statens ernæringsråd om sammensetning av kost med 60 % av energien fra 
karbohydrat, 30% fra fett og 10% fra proteiner. Frokost, lunsj og middag anbefales å inneholde lik 
energimengde mens kveldsmåltidet kan gi noe mindre. 
 
1.Frokost 
Kornblandinger, usukret (ikke cornflakes,honnikorn etc.) 
Havregrøt, bruk syltetøy og ikke sukker hvis mulig på. 
Grovt brød med ost,leverpostei (unngå her sjokoladepålegg,majones) 
Juice,melk 
Yoghurt 
Frukt og bær til å friske opp kornet. 
Egg i tillegg kan være fint . 
 
2. Lunsj 
Brød som ved frokost, med ost, syltetøy, kjøttpålegg eller leverpostei 
Ved varme lunsjer anbefales pasta og risbasert mat 
Frukt (alle typer) 
Drikke som ved frokost, mye vann dersom det har vært aktivitet på forhånd. 
 
3. Middag 
Hovedingrediensene bør bestå av følgende; 
Alltid mye poteter,kokt (ikke pommes frites!) Ris kan gi variasjon 
Mye grønnsaker (alle typer), salat 
Hoveddel bør være; fet fisk (makrell,laks,ørret), pasta, kylling/kalkunkjøtt eller rødt kjøtt (fileter), (ligg 
unna hamburgere,”junk food”,pølser etc). 
Vann 
Frukt og bær som dessert ( Ikke kaker,puddinger etc) 
 
4. Kveldsmat 
Som lunsj. 
I tillegg til disse måltidene anbefales eventuelle mellom-måltider bestående av yoghurt eller frukt. 
Unngå sjokolade etc. 
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Appendix E: Pre-test control form 
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Matinntak og fysisk aktivitetsnivå de siste dagene 
 
 
Navn: 
 
 
Har du hatt et spesielt kosthold de siste 2 dagene før i dag? Vennligst kryss av for på 
hvilken måte kostholdet eventuelt har vært spesielt: 
 
Meget fettrike måltider                                                   ja                 nei  
 
Meget magre måltider                                                    ja                 nei  
 
Meget lite inntak av karbohydrater                                ja                 nei  
 
Meget stort inntak av karbohydrater                              ja                 nei  
 
Evt. tilleggskommentarer: 
 
 
Har du spist hele det avtalte frokostmåltidet i dag, inkludert drikke?  
 
 ja                 nei  
 
Evt. kommentarer: 
 
 
 
 
 
 
Har du drevet fysisk trening eller vært meget fysisk aktiv de siste 2 dagene før i dag, og 
dagen i dag? 
 
ja                 nei  
 
Evt. kommentarer: 
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Appendix F: Visual Analogic Scale form 
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                                                      REGISTRERING AV SULTFØLELSE 
 
 
 
                                        Angi hvor sulten du er ved å sette et kryss på linjen nedenfor:  
 
 
 
 
 
 
 
 
 
 
 
 
 
                                    
______________________________________________ 
                  
              Overhodet ikke sulten                                               Ekstremt sulten 
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VURDERING AV MÅLTIDENES SMAK 
 
 
 
 
Vi er nå interessert i å vite hvordan måltidene du fikk både i dag og forrige forsøksdag 
smakte. 
 
 
Vennligst kryss av: 
 
Det ene lunsjmåltidet smakte klart bedre enn det andre: 
 
Uenig       Delvis uenig        Enig      
 
 
 
Hvis du svarte enig eller delvis uenig på forrige spørsmål, hvilket måltid smakte best? 
 
Linsemåltidet          Potetmåltidet       
 
 
 
På en skala fra 1 til 6, hvor godt smakte måltidet du fikk kl. 17 (begge forsøksdager)? 
Sett ring rundt det tallet du synes passer best, hvor 6 er meget god smak og 1 er meget 
dårlig smak.  
 
1        2         3         4           5         6    
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Appendix H: E-mail from C. Hukshorn regarding leptin’s role in obesity  
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Dear Inge Lindseth, 
 
Leptin treatment is virtually abandoned due to the fact 
that even a very high dose of this protein (as administrated 
in our own studies) fails to induce significant weight loss in obese 
individuals (on a mild hypocaloric diet). 
In addition, the costs of recombinant leptin are very high at the moment. 
In my opinion, leptin in it's current form (as a protein) has no 
therapeutical role in the treatment of obesity (see the theory of 
Dr. Flier that suggests that leptin resistance was an evolutionary 
advantage which is in line with our experimental results). 
However, it is possible that a leptin analog might still be used 
to treat obesity in the future. 
 
Sincerely, 
 
Chris Hukshorn. 
 
--  
C.J. Hukshorn, MD. 
Department of Human Biology 
Maastricht University 
PO Box 616, NL-6200 MD 
Maastricht, the Netherlands 
Phone: +31-433882112 
Fax: +31-433670976 
E-mail: c.hukshorn@hb.unimaas.nl 
 
 
 
 
 
